var title_f40_0_40960="Internal external hip rotation";
var content_f40_0_40960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Internal and external rotation of the hip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Internal and external rotation are measured to assess the integrity of the hip joint, measure rotation, and evaluate pain and stiffness. The examiner places one hand at the ankle and one hand at the knee. The lower leg is rotated laterally to test internal rotation, and medially to test external rotation. The patient is instructed to avoid rolling the buttocks during the maneuver. Internal and external rotation can be reduced by the loss of articular cartilage and outgrowth of acetabular osteophytes associated with osteoarthritis and the pain and muscle spasms of acute synovitis. Patients with severe osteoarthritis, acute synovitis, and septic arthritis may have as little as 5 to 10&ordm; of rotation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40960=[""].join("\n");
var outline_f40_0_40960=null;
var title_f40_0_40961="Candida albicans (Monilia) skin test: Drug information";
var content_f40_0_40961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Candida albicans (Monilia) skin test: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Candin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F145068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F145063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Screening for anergy: Intradermal: 0.1 mL, examine reaction site in 24-48 hours; induration &ge;5 mm in diameter is a positive reaction",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F145067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F145064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Candin&reg;: 0.1 mL/dose (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F145058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by intradermal injection into flexor surface of forearm using a tuberculin syringe with a",
"     <sup>",
"      3",
"     </sup>",
"     /",
"     <sub>",
"      8",
"     </sub>",
"     &rdquo; to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; 26- or 27-gauge needle",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F145056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Screen for detection of nonresponsiveness to antigens in immunocompromised individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F145052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13737309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40961/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8837 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-512E5AB897-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40961=[""].join("\n");
var outline_f40_0_40961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145062\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145068\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145063\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145067\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145064\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145055\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145047\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145058\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145056\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298951\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218853\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145052\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206263\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737309\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8837\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8837|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_0_40962="Advanced case 15 with answer";
var content_f40_0_40962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Isorhythmic AV dissociation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 99px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rhythm strip showing sinus rhythm with isorhythmic atrioventricular dissociation. The sinus P waves and QRS complex have a similar rate, but the P waves are not conducted as ventricular depolarization is initiated by a junctional focus. Note that the P waves appear to move into, fuse with (beats 2 and 3), and then move out of (beats 4 through 7) the QRS complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40962=[""].join("\n");
var outline_f40_0_40962=null;
var title_f40_0_40963="Aprotinin: Patient drug information";
var content_f40_0_40963=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aprotinin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/52/6982?source=see_link\">",
"     see \"Aprotinin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F136410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Trasylol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen. You will be closely watched by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691584",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower bleeding during heart surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701541",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aprotinin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697241",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had heart surgery in the past 12 months, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698125",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Heart attack may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698196",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the kidneys may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stroke may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11231 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40963=[""].join("\n");
var outline_f40_0_40963=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136410\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029439\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029441\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029440\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029444\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029445\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029447\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029443\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029448\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029449\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/52/6982?source=related_link\">",
"      Aprotinin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_0_40964="Palivizumab: Pediatric drug information";
var content_f40_0_40964=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Palivizumab: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40371?source=see_link\">",
"    see \"Palivizumab: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synagis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F205782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Synagis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Monoclonal Antibody",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      RSV, prevention:",
"     </b>",
"     I.M.: 15 mg/kg once monthly throughout RSV season;",
"     <b>",
"      Note:",
"     </b>",
"     For cardiopulmonary bypass patients, administer a dose as soon as possible after cardiopulmonary bypass procedure, even if &lt;1 month from previous dose. AAP recommends a maximum of 3 doses for patients born GA 32 weeks 0 days through 34 weeks 6 days without significant congenital heart disease or chronic lung disease and maximum of 5 doses for all others (AAP, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40371?source=see_link\">",
"      see \"Palivizumab: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      RSV, prevention:",
"     </b>",
"     Infants and Children: I.M.: 15 mg/kg once monthly throughout RSV season;",
"     <b>",
"      Note:",
"     </b>",
"     For cardiopulmonary bypass patients, administer a dose as soon as possible after cardiopulmonary bypass procedure, even if &lt;1 month from previous dose. AAP recommends a maximum of 3 doses for patients born GA 32 weeks 0 days through 34 weeks 6 days without significant congenital heart disease or chronic lung disease and maximum of 5 doses for all others (AAP, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      RSV, treatment in patients at high-risk for severe disease:",
"     </b>",
"     Limited data available: Infants, Children, and Adolescents: I.V.: 15 mg/kg as a single dose; in most patients, used in combination with ribavirin therapy; in two patients with disease progression, a single repeat dose at 3-5 days after the initial dose was reported (Ch&aacute;vez-Bueno, 2007). Dosing based on experience in 85 patients the majority of which are pediatric patients and mostly &le;2 years of age. Reported efficacy results variable, an initial double-blind, placebo-controlled trial (n= 17 treatment group; all patients &le;2 years) showed statistically significant decreases in RSV tracheal aspirate concentrations vs placebo (Malley, 1998); in another double-blind, placebo-controlled trial (n=22 treatment group; all patients &le;2 years) a decrease in the days of RSV hospitalization, days of supplemental oxygen, and lower respiratory infection scores were reported relative to placebo (S&aacute;ez-Llorens, 2004); in an underpowered, observational study of hematopoietic stem cell  patients (n=15; age range: 2-60 years) a decrease viral shedding and increased 30 day-survival vs ribavirin monotherapy (83.3% vs ~55%) was reported (Boeckh, 2001); further studies are needed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synagis&reg;: 100 mg/mL (0.5 mL, 1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Administer undiluted solution I.M., preferably in the anterolateral aspect of the thigh; gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve; injection volume over 1 mL should be given as a divided dose. Do",
"     <b>",
"      not",
"     </b>",
"     dilute product; do not shake or vigorously agitate the vial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: In clinical trials in pediatric patients &le;2 years, has been administered IVP over 2-5 minutes or I.V. infusion through a 0.2 micron filter at a rate not to exceed 1-2 mL/minute at a final concentration of 10-20 mg/mL (Boeckh, 2001; S&aacute;ez-Llorens, 2004; Subramanian, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vial at 2&deg;C to 8&deg;C (35.6&deg;F to 46.4&deg;F) in original container; do not freeze. The single-use vial does not contain a preservative.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants and children at high risk for RSV disease (FDA approved &le;24 months of age); has also been used for I.V. treatment of active RSV infections in patients at high-risk for severe disease.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The American Academy of Pediatrics recommends RSV prophylaxis with palivizumab during RSV season for:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     Infants &lt;3 months of age who were born between gestational age 32 weeks 0 days and 34 weeks 6 days and have one of the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     &bull; Daycare attendance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     &bull; &ge;1 sibling who is &lt;5 years of age living in the same household",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Infants &lt;6 months of age who were born between gestational age 29 weeks to &le;31 weeks 6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Infants &lt;12 months of age who were born gestational age &le;28 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Infants &lt;12 months of age with congenital airway abnormality or neuromuscular disorder that decreases the ability to manage airway secretions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Infants and children &lt;24 months of age with chronic lung disease (CLD) necessitating medical therapy within 6 months prior to the beginning of RSV season",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Infants and children &le;24 months with congenital heart disease and one of the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     &bull; Receiving medication to treat congestive heart failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     &bull; Moderate to severe pulmonary hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     &bull; Cyanotic heart disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Synagis&reg; may be confused with Synalgos&reg;-DC, Synflorix&trade;, Synvisc&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F205804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Antibody formation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis (very rare - includes angioedema, dyspnea, hypotonia, pruritus, respiratory failure, unresponsiveness, urticaria); hypersensitivity reactions, injection site reactions, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to palivizumab or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with thrombocytopenia or any coagulation disorder; bleeding/hematoma may occur from I.M. administration. Interference (false-negatives) with immunological-based RSV diagnostic tests (antigen-detection) and viral culture assays has been reported; rely on reverse-transcriptase-polymerase chain reaction based assays and clinical findings. Safety and efficacy have not been demonstrated for treatment of established RSV disease.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare cases of anaphylaxis have been reported following re-exposure to palivizumab. Severe acute hypersensitivity reactions have also been reported following administration of palivizumab. Palivizumab should be permanently discontinued if a severe hypersensitivity reaction occurs. If anaphylaxis or severe allergic reaction occurs, administer epinephrine (1:1000) and provide supportive care as required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for adult use; reproduction studies have not been conducted",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for anaphylactic or severe allergic reactions",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Humanized monoclonal antibody directed to an epitope in the A antigenic site of the respiratory syncytial virus F protein resulting in neutralizing and fusion-inhibitory activity against RSV",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F9626302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protective trough concentrations (&ge;40 mcg/mL) are achieved following the second dose.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;24 months: 20 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 18 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to achieve adequate serum antibody titers: 48 hours",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     RSV prophylaxis should be initiated no earlier than July 1st in Southeast Florida, September 15th in Northcentral and Southwest Florida, and November 1st in most other areas of the United States.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antipalivizumab antibodies may develop after the fourth injection in some patients (~1%).  This has not been associated with any risk of adverse events or altered serum concentrations.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Policy Statement - Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(6):1694-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40964/abstract-text/19736258/pubmed\" id=\"19736258\" target=\"_blank\">",
"        19736258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeckh M, Berrey MM, Bowden RA, et al, &ldquo;Phase 1 Evaluation of the Respiratory Syncytial Virus-Specific Monoclonal Antibody Palivizumab in Recipients of Hematopoietic Stem Cell Transplants,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 2001, 184(3):350-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40964/abstract-text/11443562/pubmed\" id=\"11443562\" target=\"_blank\">",
"        11443562",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ch&aacute;vez-Bueno S, Mej&iacute;as A, Merryman RA, et al, \"Intravenous Palivizumab and Ribavirin Combination for Respiratory Syncytial Virus Disease in High-Risk Pediatric Patients,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2007, 26(12):1089-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40964/abstract-text/18043443/pubmed\" id=\"18043443\" target=\"_blank\">",
"        18043443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feltes TF, Cabalka AK, Meissner HC, et al, &ldquo;Palivizumab Prophylaxis Reduces Hospitalization Due to Respiratory Syncytial Virus in Young Children With Hemodynamically Significant Congenital Heart Disease,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2003, 143(4):532-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40964/abstract-text/14571236/pubmed\" id=\"14571236\" target=\"_blank\">",
"        14571236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giebels K, Marcotte JE, Podoba J, et al, \"Prophylaxis Against Respiratory Syncytial Virus in Young Children With Cystic Fibrosis,\"",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2008, 43(2):169-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40964/abstract-text/18085710/pubmed\" id=\"18085710\" target=\"_blank\">",
"        18085710",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malley R, DeVincenzo J, Ramilo O, et al, \"Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein,\"",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1998, 178(6):1555-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40964/abstract-text/9815203/pubmed\" id=\"9815203\" target=\"_blank\">",
"        9815203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-Risk Infants. The Impact-RSV Study Group,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 102(3 Pt 1):531-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40964/abstract-text/9738173/pubmed\" id=\"9738173\" target=\"_blank\">",
"        9738173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      S&aacute;ez-Llorens X, Moreno MT, Ramilo O, et al, \"Safety and Pharmacokinetics of Palivizumab Therapy in Children Hospitalized With Respiratory Syncytial Virus Infection,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2004, 23(8):707-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40964/abstract-text/15295219/pubmed\" id=\"15295219\" target=\"_blank\">",
"        15295219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Subramanian KN, Weisman LE, Rhodes T, et al, \"Safety, Tolerance and Pharmacokinetics of a Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants and Infants With Bronchopulmonary Dysplasia. MEDI-493 Study Group,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1998, 17(2):110-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40964/abstract-text/9493805/pubmed\" id=\"9493805\" target=\"_blank\">",
"        9493805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12672 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40964=[""].join("\n");
var outline_f40_0_40964=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205781\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205782\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049125\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444087\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049119\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205766\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205753\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049128\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049122\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049127\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205806\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205804\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049131\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049118\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049117\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299812\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205762\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205764\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205774\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049124\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049116\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9626302\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049130\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049132\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12672\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12672|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40371?source=related_link\">",
"      Palivizumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_0_40965="Hydroxychloroquine: Pediatric drug information";
var content_f40_0_40965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroxychloroquine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"    see \"Hydroxychloroquine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/39/18037?source=see_link\">",
"    see \"Hydroxychloroquine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Plaquenil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydroxyquine&reg;;",
"     </li>",
"     <li>",
"      Gen-Hydroxychloroquine;",
"     </li>",
"     <li>",
"      Mylan-Hydroxychloroquine;",
"     </li>",
"     <li>",
"      Plaquenil&reg;;",
"     </li>",
"     <li>",
"      PRO-Hydroxyquine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimalarial Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antirheumatic, Disease Modifying",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"      see \"Hydroxychloroquine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chemoprophylaxis of malaria: 5 mg/kg",
"     <b>",
"      (base)",
"     </b>",
"     once weekly; do not exceed the recommended adult dose; begin 2 weeks before exposure; continue for 4 weeks after leaving endemic area",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uncomplicated acute attack of malaria: 10 mg/kg",
"     <b>",
"      (base)",
"     </b>",
"     initial dose; followed by 5 mg/kg",
"     <b>",
"      (base)",
"     </b>",
"     in 6-8 hours on day 1; 5 mg/kg",
"     <b>",
"      (base)",
"     </b>",
"     as a single dose on day 2 and on day 3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     JRA or SLE: 3-5 mg/kg/day",
"     <b>",
"      (as sulfate)",
"     </b>",
"     divided 1-2 times/day to a maximum of 400 mg/day",
"     <b>",
"      (as sulfate)",
"     </b>",
"     ; not to exceed 7 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chemoprophylaxis of malaria: 310 mg",
"     <b>",
"      (base)",
"     </b>",
"     once weekly on same day each week; begin 2 weeks before exposure; continue for 4 weeks after leaving endemic area",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uncomplicated acute attack of malaria: 620 mg",
"     <b>",
"      (base)",
"     </b>",
"     first dose day one; 310 mg",
"     <b>",
"      (base)",
"     </b>",
"     in 6-8 hours day one; 310 mg",
"     <b>",
"      (base)",
"     </b>",
"     as a single dose day 2; and 310 mg",
"     <b>",
"      (base)",
"     </b>",
"     as a single dose on day 3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rheumatoid arthritis: 400-600 mg/day",
"     <b>",
"      (as sulfate)",
"     </b>",
"     once daily to start; increase dose until optimum response level is reached; usually after 4-12 weeks dose should be reduced by 50% and a maintenance dose given of 200-400 mg/day",
"     <b>",
"      (as sulfate)",
"     </b>",
"     divided 1-2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lupus erythematosus: 400 mg",
"     <b>",
"      (as sulfate)",
"     </b>",
"     every day or twice daily for several weeks depending on response; 200-400 mg/day",
"     <b>",
"      (as sulfate)",
"     </b>",
"     for prolonged maintenance therapy",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 200 mg [equivalent to 155 mg base]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plaquenil&reg;: 200 mg [equivalent to 155 mg base]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or milk to decrease GI distress",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets at room temperature; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppression or treatment of malaria caused by susceptible",
"     <i>",
"      P. vivax",
"     </i>",
"     ,",
"     <i>",
"      P. ovale",
"     </i>",
"     ,",
"     <i>",
"      P. malariae",
"     </i>",
"     , and some strains of",
"     <i>",
"      P. falciparum",
"     </i>",
"     (not effective against chloroquine-resistant strains of",
"     <i>",
"      P. falciparum",
"     </i>",
"     ; not active against pre-erythrocytic or exoerythrocytic tissue stages of",
"     <i>",
"      Plasmodium",
"     </i>",
"     ); treatment of systemic lupus erythematosus (SLE) and acute or chronic rheumatoid arthritis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F180902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hydroxychloroquine may be confused with hydrocortisone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Plaquenil&reg; may be confused with Platinol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F180900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiomyopathy (rare, relationship to hydroxychloroquine unclear)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, dizziness, emotional changes, headache, irritability, lassitude, nervousness, nightmares, psychosis, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, bleaching of hair, pigmentation changes (skin and mucosal; black-blue color), rash (acute generalized exanthematous pustulosis, erythema annulare centrifugum, exfoliative dermatitis, lichenoid, maculopapular, morbilliform, purpuric, Stevens-Johnson syndrome, urticarial), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramping, anorexia, diarrhea, nausea, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolysis (in patients with glucose-6-phosphate deficiency), leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal liver function/hepatic failure (isolated cases)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myopathy, palsy, or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups (may be associated with mild sensory changes, loss of deep tendon reflexes, and abnormal nerve conduction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal color vision, abnormal retinal pigmentation, atrophy, attenuation of retinal arterioles, corneal changes/deposits (visual disturbances, blurred vision, photophobia [reversible on discontinuation]), decreased visual acuity, disturbance in accommodation, keratopathy, macular edema, nystagmus, optic disc pallor/atrophy, pigmentary retinopathy, retinopathy (early changes reversible [may progress despite discontinuation if advanced]), scotoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Deafness, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Exacerbation of porphyria and nonlight sensitive psoriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, respiratory failure (myopathy-related)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxychloroquine, 4-aminoquinoline derivatives, or any component; retinal or visual field changes; patients with porphyria or psoriasis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic disease, G-6-PD deficiency, and patients on concurrent therapy with known hepatotoxic drugs",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children are especially sensitive to 4-aminoquinoline compounds; long-term use in children is contraindicated; daily dose &gt;6-6.5 mg/kg/day in patients with abnormal hepatic or renal function may be associated with an increased risk of retinal toxicity",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F180831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anthelmintics: Aminoquinolines (Antimalarial) may decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Aminoquinolines (Antimalarial) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoquinolines (Antimalarial) may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: Aminoquinolines (Antimalarial) may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of Aminoquinolines (Antimalarial).  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Hydroxychloroquine may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1047745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food increases bioavailability",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5265901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Malaria infection in pregnant women may be more severe than in nonpregnant women. Therefore, pregnant women and women who are likely to become pregnant are advised to avoid travel to malaria-risk areas. Hydroxychloroquine is recommended as an alternative treatment of pregnant women for uncomplicated malaria in chloroquine-sensitive regions. Women exposed to hydroxychloroquine for the  treatment of rheumatoid arthritis or systemic lupus erythematosus during pregnancy may be enrolled in the Organization of Teratology Information Specialists (OTIS) Autoimmune Diseases Study pregnancy registry (877-311-8972).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmologic examination at baseline and every 3 months with prolonged therapy (including visual acuity, slit-lamp, fundoscopic, and visual field exam), CBC with differential and platelet count; check for muscular weakness with prolonged therapy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with digestive vacuole function within sensitive malarial parasites by increasing the pH and interfering with lysosomal degradation of hemoglobin; inhibits locomotion of neutrophils and chemotaxis of eosinophils; impairs complement-dependent antigen-antibody reactions",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1047741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action for JRA: 2-4 months, up to 6 months",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Highly variable (31% to 100%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive distribution to most body fluids and tissues; excreted into breast milk; crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Increased when administered with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Metabolites and unchanged drug slowly excreted in the urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/39/18037?source=see_link\">",
"      see \"Hydroxychloroquine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Notify physician if blurring of vision, vision change, weakness, numbness, tremors, rash, persistent diarrhea, or emotional change occur. May cause dizziness and vision changes, so exercise caution when driving; avoid alcohol; contraindicated during breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F180840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 25 mg/mL hydroxychloroquine sulfate oral suspension may be made with tablets. With a towel moistened with alcohol, remove the coating from fifteen 200 mg hydroxychloroquine sulfate tablets. Crush tablets in a mortar and reduce to a fine powder. Add 15 mL of Ora-Plus&reg; and mix to a uniform paste; add an additional 45 mL of vehicle and mix until uniform. Mix while adding sterile water for irrigation in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with sterile water, and add sufficient quantity of sterile water to make 120 mL. Label \"shake well\". A 30-day expiration date is recommended, although stability testing has not been performed.",
"    </p>",
"    <div class=\"reference\">",
"     Pesko LJ, \"Compounding: Hydroxychloroquine,\"",
"     <i>",
"      Am Druggist",
"     </i>",
"     , 1993, 207(4):57.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Treatment of Malaria in the United States,&rdquo; available at",
"      <a href=\"file://www.cdc.gov/malaria/diagnosis_treatment/tx_clinicians.htm\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/diagnosis_treatment/tx_clinicians.htm",
"      </a>",
"      and",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"      ; last accessed October 2, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emery H, &ldquo;Clinical Aspects of Systemic Lupus Erythematosus in Childhood,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1986, 33(5):1177-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40965/abstract-text/3763254/pubmed\" id=\"3763254\" target=\"_blank\">",
"        3763254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giannini EH and Cawkwell GD, &ldquo;Drug Treatment in Children With Juvenile Rheumatoid Arthritis. Past, Present, and Future,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1995, 42(5):1099-125.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40965/abstract-text/7567188 /pubmed\" id=\"7567188 \" target=\"_blank\">",
"        7567188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Management of Rheumatoid Arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1996, 39(5):713-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40965/abstract-text/8639167/pubmed\" id=\"8639167\" target=\"_blank\">",
"        8639167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13366 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40965=[""].join("\n");
var outline_f40_0_40965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708908\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180857\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180858\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047734\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047727\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180836\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180822\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047738\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047730\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047737\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180902\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180900\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047743\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047726\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047725\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299491\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180831\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047745\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5265901\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047733\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047724\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047741\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047742\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047732\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180840\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13366\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13366|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=related_link\">",
"      Hydroxychloroquine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/39/18037?source=related_link\">",
"      Hydroxychloroquine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_0_40966="Alprostadil: Drug information";
var content_f40_0_40966=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alprostadil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/15/23796?source=see_link\">",
"    see \"Alprostadil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/57/23445?source=see_link\">",
"    see \"Alprostadil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Caverject Impulse&reg;;",
"     </li>",
"     <li>",
"      Caverject&reg;;",
"     </li>",
"     <li>",
"      Edex&reg;;",
"     </li>",
"     <li>",
"      Muse&reg;;",
"     </li>",
"     <li>",
"      Prostin VR Pediatric&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alprostadil Injection USP;",
"     </li>",
"     <li>",
"      Caverject&reg;;",
"     </li>",
"     <li>",
"      Muse&reg; Pellet;",
"     </li>",
"     <li>",
"      Prostin&reg; VR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F132207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Prostaglandin;",
"     </li>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F132171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Erectile dysfunction:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intracavernous (Caverject&reg;, Edex&reg;):",
"     </i>",
"     Individualize dose by careful titration; doses &gt;40 mcg (Edex&reg;) or &gt;60 mcg (Caverject&reg;) are not recommended: Initial dose must be titrated in physician's office. Patient must stay in the physician's office until complete detumescence occurs; if there is no response, then the next higher dose may be given within 1 hour; if there is still no response, a 1-day interval before giving the next dose is recommended; increasing the dose or concentration in the treatment of impotence results in increasing pain and discomfort.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vasculogenic, psychogenic, or mixed etiology: Initiate dosage titration at 2.5 mcg, increasing by 2.5 mcg to a dose of 5 mcg and then in increments of 5-10 mcg depending on the erectile response until the dose produces an erection suitable for intercourse, not lasting &gt;1 hour; if there is absolutely no response to initial 2.5 mcg dose, the second dose may be increased to 7.5 mcg, followed by increments of 5-10 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neurogenic etiology (eg, spinal cord injury): Initiate dosage titration at 1.25 mcg, increasing to a dose of 2.5 mcg and then 5 mcg; increase further in increments 5 mcg until the dose is reached that produces an erection suitable for intercourse, not lasting &gt;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: Once appropriate dose has been determined, patient may self-administer injections at a frequency of no more than 3 times/week with at least 24 hours between doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intraurethral (Muse&reg; Pellet):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 125-250 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: Administer as needed to achieve an erection; duration of action is about 30-60 minutes; use only two systems per 24-hour period",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F132189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/57/23445?source=see_link\">",
"      see \"Alprostadil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patent ductus arteriosus",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prostin VR Pediatric&reg;:",
"     </i>",
"     I.V. continuous infusion into a large vein, or alternatively through an umbilical artery catheter placed at the ductal opening: 0.05-0.1 mcg/kg/minute with therapeutic response, rate is reduced to lowest effective dosage. With unsatisfactory response, rate is increased gradually; maintenance: 0.01-0.4 mcg/kg/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     PGE",
"     <sub>",
"      1",
"     </sub>",
"     is usually given at an infusion rate of 0.1 mcg/kg/minute, but it is often possible to reduce the dosage to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     or even",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      10",
"     </sub>",
"     without losing the therapeutic effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapeutic response is indicated by increased pH in those with acidosis or by an increase in oxygenation (PO",
"     <sub>",
"      2",
"     </sub>",
"     ) usually evident within 30 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F132172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elderly patients may have a greater frequency of renal dysfunction; lowest effective dose should be used. In clinical studies with Edex&reg;, higher minimally effective doses and a higher rate of lack of effect were noted.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caverject Impulse&reg;: 10 mcg, 20 mcg [contains benzyl alcohol (in diluent), lactose 45.4 mg; cartridge; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caverject&reg;: 20 mcg, 40 mcg [contains benzyl alcohol (in diluent), lactose 172 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edex&reg;: 10 mcg, 20 mcg, 40 mcg [contains lactose 51.06 mg; cartridge; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 500 mcg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prostin VR Pediatric&reg;: 500 mcg/mL (1 mL) [contains dehydrated ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pellet, urethral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Muse&reg;: 125 mcg (1s, 6s); 250 mcg (1s, 6s); 500 mcg (1s, 6s); 1000 mcg (1s, 6s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution for injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F132147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patent ductus arteriosus (Prostin VR Pediatric&reg;): I.V. continuous infusion into a large vein or alternatively through an umbilical artery catheter placed at the ductal opening; manufacturer recommended maximum concentration for I.V. infusion: 20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erectile dysfunction: Use a",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch, 27- to 30-gauge needle. Inject into the dorsolateral aspect of the proximal third of the penis, avoiding visible veins; alternate side of the penis for injections.",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10 mcg/mL",
"     <b>",
"      or",
"     </b>",
"     20 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F132146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prostin VR Pediatric&reg;: Temporary maintenance of patency of ductus arteriosus in neonates with ductal-dependent congenital heart disease until surgery can be performed. These defects include cyanotic (eg, pulmonary atresia, pulmonary stenosis, tricuspid atresia, Fallot's tetralogy, transposition of the great vessels) and acyanotic (eg, interruption of aortic arch, coarctation of aorta, hypoplastic left ventricle) heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caverject&reg;: Treatment of erectile dysfunction of vasculogenic, psychogenic, or neurogenic etiology; adjunct in the diagnosis of erectile dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Edex&reg;, Muse&reg;: Treatment of erectile dysfunction of vasculogenic, psychogenic, or neurogenic etiology",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13706238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pulmonary hypertension in infants and children with congenital heart defects with left-to-right shunts",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F132214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Alprostadil may be confused with alPRAZolam",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F132205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intraurethral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Genitourinary: Penile pain, urethral burning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache, dizziness, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal itching (female partner), testicular pain, urethral bleeding (minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Tachycardia, perineal pain, leg pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intracavernosal injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Genitourinary: Penile pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache, dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Prolonged erection (&gt;4 hours, 4%), penile fibrosis, penis disorder, penile rash, penile edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site hematoma and/or bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Balanitis, injection site hemorrhage, priapism (0.4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intravenous:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Apnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hyper-/hypotension, tachycardia, cardiac arrest, edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Seizure, headache, dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Disseminated intravascular coagulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection, flu syndrome, sinusitis, nasal congestion, cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Sepsis, localized pain in structures other than the injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anemia, anuria, bleeding, bradypnea, bronchial wheezing, cerebral bleeding, CHF, gastric regurgitation, hematuria, hyperbilirubinemia, hyperemia, hyperextension of neck, hyperirritability, hyperkalemia, hypoglycemia, hypothermia, jitteriness, lethargy, peritonitis, second-degree heart block, shock, stiffness, supraventricular tachycardia, thrombocytopenia, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F132150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alprostadil or any component of the formulation; hyaline membrane disease or persistent fetal circulation and when a dominant left-to-right shunt is present; respiratory distress syndrome; conditions predisposing patients to priapism (sickle cell anemia, multiple myeloma, leukemia); patients with anatomical deformation of the penis, penile implants; use in men for whom sexual activity is inadvisable or contraindicated; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F132133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Apnea:",
"     <b>",
"      [U.S. Boxed Warning]: Apnea may occur in 10% to 12% of neonates with congenital heart defects, especially in those weighing &lt;2 kg at birth.",
"     </b>",
"     Apnea usually appears during the first hour of drug infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Erectile dysfunction: Appropriate use: When used in erectile dysfunction, priapism may occur; patient must be instructed to report to physician or seek immediate medical assistance if an erection persists for longer than 4 hours. Treat immediately to avoid penile tissue damage and permanent loss of potency; discontinue therapy if signs of penile fibrosis develop (penile angulation, cavernosal fibrosis, or Peyronie's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patency of ductus arteriosus: Appropriate use: Infuse for the shortest time at the lowest dose consistent with good patient care. Use for &gt;120 hours has been associated with antral hyperplasia and gastric outlet obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates: Use with caution in neonates with bleeding tendencies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Muse&reg;:  When used in erectile dysfunction, syncope occurring within 1 hour of administration has been reported. The potential for drug-drug interactions may occur when prescribed concomitantly with antihypertensives. Some lowering of blood pressure may occur without symptoms, and swelling of leg veins, leg pain, perineal pain, and rapid pulse have been reported in &lt;2% of patients during in-clinic titration and home treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of Alprostadil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F132163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid concurrent use (vasodilating effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X/C (Muse&reg;) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F132153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alprostadil is embryotoxic in animal studies. It is not indicated for use in women. The manufacturer of Muse&reg; recommends a condom barrier when being used during sexual intercourse with a pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F132174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in women",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F132152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Caverject Impulse Intracavernosal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mcg (1): $44.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mcg (1): $57.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pellet",
"     </b>",
"     (Muse Urethral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mcg (1): $52.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mcg (1): $54.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg (1): $58.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mcg (1): $63.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Alprostadil Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg/mL (1 mL): $48.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Prostin VR Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg/mL (1 mL): $108.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Caverject Intracavernosal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mcg (1): $54.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mcg (1): $71.23",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F132142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Arterial pressure, respiratory rate, heart rate, temperature, degree of penile pain, length of erection, signs of infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F132154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alostin (KP);",
"     </li>",
"     <li>",
"      Alprostan (RU);",
"     </li>",
"     <li>",
"      Alprostapint (BG, HU);",
"     </li>",
"     <li>",
"      Caverject (AE, AR, AT, BB, BH, BM, BO, BR, BS, BZ, CN, CO, CR, CY, CZ, DE, DO, EC, EE, EG, FR, GB, GT, GY, HU, IE, IQ, IR, JM, JO, KP, KW, LB, LU, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PR, PT, PY, QA, SA, SE, SG, SR, SV, SY, TT, TW, UY, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Caverject Dual Chamber (FR, HK);",
"     </li>",
"     <li>",
"      Caverject Impulse (AU);",
"     </li>",
"     <li>",
"      Caverjet (IL);",
"     </li>",
"     <li>",
"      Edex (FR);",
"     </li>",
"     <li>",
"      Eglandin (KP);",
"     </li>",
"     <li>",
"      Gaverject (PK);",
"     </li>",
"     <li>",
"      Liple (JP);",
"     </li>",
"     <li>",
"      Minprog (AT);",
"     </li>",
"     <li>",
"      Muse (AE, BH, CY, EG, GB, IE, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE, ZA);",
"     </li>",
"     <li>",
"      Palux (JP);",
"     </li>",
"     <li>",
"      Prink (KP);",
"     </li>",
"     <li>",
"      Promostan (TW);",
"     </li>",
"     <li>",
"      Prostandin (JP, KP);",
"     </li>",
"     <li>",
"      Prostavasin (AR, BR, CL, HU, LU, PH, UY);",
"     </li>",
"     <li>",
"      Prostin (CZ);",
"     </li>",
"     <li>",
"      Prostin Pediatrico (CN);",
"     </li>",
"     <li>",
"      Prostin VR (AE, AU, BE, BH, CH, CO, CY, EG, GB, GR, HN, HU, IL, IN, IQ, IR, IT, JO, KW, LB, LY, NL, NZ, OM, PL, QA, SA, SY, TH, TW, YE, ZA);",
"     </li>",
"     <li>",
"      Prostin VR Paedeatric (MY);",
"     </li>",
"     <li>",
"      Prostine VR (FR);",
"     </li>",
"     <li>",
"      Prostivas (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Sugiran (ES);",
"     </li>",
"     <li>",
"      Viridal (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F132132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes vasodilation by means of direct effect on vascular and ductus arteriosus smooth muscle; relaxes trabecular smooth muscle by dilation of cavernosal arteries when injected along the penile shaft, allowing blood flow to and entrapment in the lacunar spaces of the penis (ie, corporeal veno-occlusive mechanism)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F132149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &lt;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Insignificant following penile injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 81% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: ~75% by oxidation in one pass via lungs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90% as metabolites) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40966/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011.  Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peled N, Dagan O, Babyn P, et al, &ldquo;Gastric-Outlet Obstruction Induced by Prostaglandin Therapy in Neonates,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(8):505-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40966/abstract-text/1635565/pubmed\" id=\"1635565\" target=\"_blank\">",
"        1635565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40966/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weesner KM, &ldquo;Hemodynamic Effects of Prostaglandin E",
"      <sub>",
"       1",
"      </sub>",
"      in Patients With Congenital Heart Disease and Pulmonary Hypertension,&rdquo;",
"      <i>",
"       Cathet Cardiovasc Diagn",
"      </i>",
"      , 1991, 24(1):10-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40966/abstract-text/1913785/pubmed\" id=\"1913785\" target=\"_blank\">",
"        1913785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams G, Abbou CC, Amar ET, et al, &ldquo;The Effect of Transurethral Alprostadil on the Quality of Life of Men With Erectile Dysfunction, and Their Partners. MUSE Study Group,&rdquo;",
"      <i>",
"       Br J Urol",
"      </i>",
"      , 1998, 82(6):847-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40966/abstract-text/9883223/pubmed\" id=\"9883223\" target=\"_blank\">",
"        9883223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woo K, Emery J, and Peabody J, &ldquo;Cortical Hyperostosis: A Complication of Prolonged Prostaglandin Infusion in Infants Awaiting Cardiac Transplantation,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1994, 93(3):417-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40966/abstract-text/8115200/pubmed\" id=\"8115200\" target=\"_blank\">",
"        8115200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8459 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40966=[""].join("\n");
var outline_f40_0_40966=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708622\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132167\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132168\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132207\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132171\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132189\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132172\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671405\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671406\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132144\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132129\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132147\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471275\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132146\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706238\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132214\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132205\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132150\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132133\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298715\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132138\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132163\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132140\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132153\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132174\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132152\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132142\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132154\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132132\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132149\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8459\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8459|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/15/23796?source=related_link\">",
"      Alprostadil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/57/23445?source=related_link\">",
"      Alprostadil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_0_40967="Capecitabine: Drug information";
var content_f40_0_40967=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Capecitabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/53/14165?source=see_link\">",
"    see \"Capecitabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xeloda&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xeloda&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F145191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Pyrimidine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F145144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Details concerning dosing in combination regimens should also be consulted. Capecitabine toxicities, particularly hand-foot syndrome, may be higher in North American populations (for the treatment of colorectal cancer); therapy initiation at doses of 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily (for 2 weeks every 21 days) may be considered (Haller, 2008; NCCN Colon Cancer Guidelines)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metastatic breast cancer, metastatic colorectal cancer: Oral: 1250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily (morning and evening) for 2 weeks, every 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Adjuvant therapy of Dukes' C colon cancer: Recommended for a total of 24 weeks (8 cycles of 2 weeks of drug administration and 1 week rest period).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Pancreatic cancer (unlabeled use): 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily for 2 weeks, every 21 days (NCCN Pancreatic Cancer Guidelines v.1.2009)",
"     <b>",
"      or",
"     </b>",
"     1250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily for 2 weeks, every 21 days (Cartwright, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F145145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The elderly may be more sensitive to the toxic effects of fluorouracil. Insufficient data are available to provide dosage modifications.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F145146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     51-80 mL/minute: No adjustment of initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Administer 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F145147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No starting dose adjustment is necessary; however, carefully monitor patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment: Patients have not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F145192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     <b>",
"      Dosage modification guidelines:",
"     </b>",
"     See table.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Refer to package labeling for modifications when administered in combination with docetaxel.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Dose Modifications",
"     </caption>",
"     <col align=\"left\" width=\"130\">",
"     </col>",
"     <col align=\"left\" width=\"250\">",
"     </col>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Toxicity NCI Grades",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         During a Course of Therapy (Monotherapy)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose Adjustment for Next Cycle (% of starting dose)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Grade 1",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Grade 2",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         1st appearance",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Interrupt until resolved to grade 0-1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         2nd appearance",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Interrupt until resolved to grade 0-1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         3rd appearance",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Interrupt until resolved to grade 0-1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         4th appearance",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue treatment permanently",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Grade 3",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         1st appearance",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Interrupt until resolved to grade 0-1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         2nd appearance",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Interrupt until resolved to grade 0-1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         3rd appearance",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue treatment permanently",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Grade 4",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         1st appearance",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue permanently",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          or",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         If physician deems it to be in the patient's best interest to continue, interrupt until resolved to grade 0-1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50%",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustments for hematologic toxicity in combination therapy with ixabepilone:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Neutrophils &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &ge;7 days or neutropenic fever: Hold for concurrent diarrhea or stomatitis until neutrophils recover to &gt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , then continue at same dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (or &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     with bleeding): Hold for concurrent diarrhea or stomatitis until platelets recover to &gt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , then continue at same dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xeloda&reg;: 150 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F145120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usually administered in 2 divided doses taken 12 hours apart. Doses should be taken with water within 30 minutes after a meal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F145119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic colorectal cancer; adjuvant therapy of Dukes' C colon cancer; treatment of metastatic breast cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5583457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of gastric cancer, pancreatic cancer, esophageal cancer, ovarian cancer, metastatic renal cell cancer, neuroendocrine tumors, metastatic CNS lesions",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2704106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Xeloda&reg; may be confused with Xenical&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F145189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency listed derived from monotherapy trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (9% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (16% to 42%), fever (7% to 18%), pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Palmar-plantar erythrodysesthesia (hand-and-foot syndrome) (54% to 60%; grade 3: 11% to 17%; may be dose limiting), dermatitis (27% to 37%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (47% to 57%; may be dose limiting; grade 3: 12% to 13%; grade 4: 2% to 3%), nausea (34% to 53%), vomiting (15% to 37%), abdominal pain (7% to 35%), stomatitis (22% to 25%), appetite decreased (26%), anorexia (9% to 23%), constipation (9% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Lymphopenia (94%; grade 4: 14%), anemia (72% to 80%; grade 4: &lt;1% to 1%), neutropenia (2% to 26%; grade 4: 2%), thrombocytopenia (24%; grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (22% to 48%; grades 3/4: 11% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Eye irritation (13% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Venous thrombosis (8%), chest pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5% to 10%), lethargy (10%), dizziness (6% to 8%), insomnia (7% to 8%), mood alteration (5%), depression (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Nail disorder (7%), rash (7%), skin discoloration (7%), alopecia (6%), erythema (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Motility disorder (10%), oral discomfort (10%), dyspepsia (6% to 8%), upper GI inflammatory disorders (colorectal cancer: 8%), hemorrhage (6%), ileus (6%), taste perversion (colorectal cancer: 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (10%), weakness (10%), neuropathy (10%), myalgia (9%), arthralgia (8%), limb pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision (colorectal cancer: 5%), conjunctivitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (colorectal cancer: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5% (Limited to important or life-threatening): Angina, ascites, asthma, atrial fibrillation, bradycardia, bronchitis, bronchopneumonia, bronchospasm, cachexia, cardiac arrest, cardiac failure, cardiomyopathy, cerebral vascular accident, cholestatic hepatitis, coagulation disorder, colitis, confusion, deep vein thrombosis, diaphoresis, duodenitis, dysarthria, dysphagia, dysrhythmia, ecchymoses, ECG changes, encephalopathy, epistaxis, esophagitis, fibrosis, fingerprint distortion (secondary to hand-and-foot syndrome), fungal infection, gastric ulcer, gastritis, gastroenteritis, gastrointestinal perforation, hematemesis, hemoptysis, hepatic failure, hepatic fibrosis, hepatitis, hypokalemia, hypomagnesemia, hyper-/hypotension, hypersensitivity, hypertriglyceridemia, idiopathic thrombocytopenia purpura, ileus, infection, intestinal obstruction (~1%), keratoconjunctivitis, lacrimal duct stenosis, leukopenia, loss of consciousness, lymphedema, MI, multifocal leukoencephalopathy, myocardial ischemia, myocarditis, necrotizing enterocolitis (typhlitis), oral candidiasis, pericardial effusion, thrombocytopenic purpura, pancytopenia, photosensitivity reaction, pneumonia, pruritus, pulmonary embolism, radiation recall syndrome, renal impairment, respiratory distress, sedation, sepsis, skin ulceration, Stevens-Johnson syndrome, tachycardia, thrombophlebitis, toxic epidermal necrolysis, toxic megacolon, tremor, ventricular extrasystoles",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F145123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to capecitabine, fluorouracil, or any component of the formulation; known deficiency of dihydropyrimidine dehydrogenase (DPD); severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F145105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiotoxicity: There has been cardiotoxicity associated with fluorinated pyrimidine therapy, including myocardial infarction, angina, dysrhythmias, cardiogenic shock, sudden death, ECG changes, and cardiomyopathy. These adverse events may be more common in patients with a history of coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: Can cause severe diarrhea; median time to first occurrence is 34 days; subsequent doses should be reduced after grade 3 or 4 diarrhea or recurrence of grade 2 diarrhea. Dehydration may occur rapidly in patients with diarrhea, nausea, vomiting, anorexia, and/or weakness; adequately hydrate prior to treatment initiation. Elderly patients may be a higher risk for dehydration.",
"     <b>",
"      Note:",
"     </b>",
"     The Canadian labeling recommends treatment interruption for dehydration requiring I.V. hydration lasting &lt;24 hours or dosage reduction if I.V hydration required for &ge;24 hours; correct precipitating factors and ensure rehydration prior to resuming therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hand-and-foot syndrome: May cause hand-and-foot syndrome (palmar-plantar erythrodysesthesia or chemotherapy-induced acral erythema) is characterized by numbness, dysesthesia/paresthesia, tingling, painless or painful swelling, erythema, desquamation, blistering, and severe pain. If grade 2 or 3 hand-and-foot syndrome occurs, interrupt administration of capecitabine until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-and-foot syndrome, decrease subsequent doses of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Necrotizing enterocolitis (typhlitis): Has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Bone marrow suppression may occur, hematologic toxicity is more common when used in combination therapy; use with caution; dosage adjustments may be required. Canadian labeling recommends that patients with baseline platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or neutrophils &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     not receive capecitabine therapy and also to withhold therapy for grade 3 or 4 hematologic toxicity during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dihydropyrimidine dehydrogenase (DPD) deficiency: Rare and unexpected severe toxicity (stomatitis, diarrhea, neutropenia, neurotoxicity) may be attributed to dihydropyrimidine dehydrogenase (DPD) deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; reduce dose with moderate impairment and carefully monitor and reduce subsequent dose (with any grade 2 or higher adverse effect) with mild-to-moderate impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alkylating therapy: Use with caution in patients who have received alkylating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluorouracil/leucovorin (FU/LV): In patients with colorectal cancer, treatment with capecitabine immediately following 6 weeks of FU/LV therapy has been associated with an increased incidence of grade &ge;3 toxicity, when compared to patients receiving the reverse sequence, capecitabine (two 3-week courses) followed by FU/LV (Hennig, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Warfarin:",
"     <b>",
"      [U.S. Boxed Warning]: Capecitabine may increase the anticoagulant effects of warfarin; monitor closely.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &ge;80 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pelvic radiation therapy recipients: Use with caution in patients who have received extensive pelvic radiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2706932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Capecitabine may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May enhance the adverse/toxic effect of Capecitabine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Capecitabine may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Capecitabine may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F145137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food reduced the rate and extent of absorption of capecitabine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F145112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F145126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenicity and fetal loss. There are no adequate and well-controlled studies in pregnant women; however, fetal harm may occur. Women of childbearing potential should avoid pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F145153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F145127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if the drug is excreted in breast milk. Because of the potential for serious adverse reactions in nursing infants, it is recommended that nursing be discontinued when receiving capecitabine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F145128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because current safety and efficacy data are based upon administration with food, it is recommended that capecitabine be administered with food. In all clinical trials, patients were instructed to take  with water within 30 minutes after a meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F145125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Xeloda Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $690.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (120): $4601.11",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F145114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function should be estimated at baseline to determine initial dose. During therapy, CBC with differential, hepatic function, and renal function should be monitored.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F145129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apecitab (AR);",
"     </li>",
"     <li>",
"      Capecitabina (PE);",
"     </li>",
"     <li>",
"      Capibine (IN);",
"     </li>",
"     <li>",
"      Xeloda (AR, AT, AU, BB, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CZ, DE, DK, EC, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, ID, IE, IL, IS, IT, JM, KE, KP, LR, LU, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, PH, PK, PL, PT, PY, RU, SC, SD, SE, SG, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F145104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capecitabine is a prodrug of fluorouracil. It undergoes hydrolysis in the liver and tissues to form fluorouracil which is the active moiety. Fluorouracil is a fluorinated pyrimidine antimetabolite that inhibits thymidylate synthetase, blocking the methylation of deoxyuridylic acid to thymidylic acid, interfering with DNA, and to a lesser degree, RNA synthesis. Fluorouracil appears to be phase specific for the G",
"     <sub>",
"      1",
"     </sub>",
"     and S phases of the cell cycle.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F145122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and extensive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;60%; ~35% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Inactive metabolites: 5&prime;-deoxy-5-fluorocytidine, 5&prime;-deoxy-5-fluorouridine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tissue: Active metabolite: Fluorouracil",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1.5 hours; Fluorouracil: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (96%, 57% as &alpha;-fluoro-&beta;-alanine); feces (&lt;3%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bamat MK, Tremmel R, O&rsquo;Neil JD, et al, &ldquo;Uridine Triacetate: An Orally Administered Life-Saving Antidote for 5-FU Overdose,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 28(15s):9084 [abstract 9084 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cartwright TH, Cohn A, Varkey JA, et al, &ldquo;Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(1):160-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/11773165/pubmed\" id=\"11773165\" target=\"_blank\">",
"        11773165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cassidy J, Tabernero J, Twelves C, et al, \"XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(11):2084-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/15169795/pubmed\" id=\"15169795\" target=\"_blank\">",
"        15169795",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haller DG, Cassidy J, Clarke S, et al, &ldquo;Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008,  26(13):2118-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/18445840/pubmed\" id=\"18445840\" target=\"_blank\">",
"        18445840",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hennig IM, Naik JD, Brrown S, et al, &ldquo;Severe Sequence-Specific Toxicity When Capecitabine Is Given After Fluorouracil and Leucovorin,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(20):3411-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/18612156/pubmed\" id=\"18612156\" target=\"_blank\">",
"        18612156",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoff PM, Ansari R, Batist G, et al, &ldquo;Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(8):2282-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/11304782/pubmed\" id=\"11304782\" target=\"_blank\">",
"        11304782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ishitsuka H, &ldquo;Capecitabine: Preclinical Pharmacology Studies,&rdquo;",
"      <i>",
"       Invest New Drugs",
"      </i>",
"      , 2000, 18(4):343-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/11081570/pubmed\" id=\"11081570\" target=\"_blank\">",
"        11081570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnston PG and Kaye S, &ldquo;Capecitabine: A Novel Agent for the Treatment of Solid Tumors,&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 2001, 12(8):639-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/11604550/pubmed\" id=\"11604550\" target=\"_blank\">",
"        11604550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Judson IR, Beale PJ, Trigo JM, et al, &ldquo;A Human Capecitabine Excretion Balance and Pharmacokinetic Study After Administration of a Single Oral Dose of",
"      <sup>",
"       14",
"      </sup>",
"      C-Labelled Drug,&rdquo;",
"      <i>",
"       Invest New Drugs",
"      </i>",
"      , 1999, 17(1):49-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/15173095/pubmed\" id=\"15173095\" target=\"_blank\">",
"        15173095",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGavin JK and Goa KL, &ldquo;Capecitabine: A Review of Its Use in the Treatment of Advanced or Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2001, 61(15):2309-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/11772141/pubmed\" id=\"11772141\" target=\"_blank\">",
"        11772141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prevention and Treatment of Colon Cancer,&rdquo; Version 2.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/colon.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prevention and Treatment of Pancreatic Adenocarcinoma,&rdquo; Version 1.2009. Available at file://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schilsky RL, &ldquo;Pharmacology and Clinical Status of Capecitabine,&rdquo;",
"      <i>",
"       Oncology",
"      </i>",
"      , 2000, 14(9):1297-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/11033828/pubmed\" id=\"11033828\" target=\"_blank\">",
"        11033828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Twelves C, Wong A, Nowacki MP, et al, &ldquo;Capecitabine as Adjuvant Treatment for Stage III Colon Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(26):2696-704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/15987918/pubmed\" id=\"15987918\" target=\"_blank\">",
"        15987918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Cutsem E, Twelves C, Cassidy J, et al, &ldquo;Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(21):4097-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/11689577/pubmed\" id=\"11689577\" target=\"_blank\">",
"        11689577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Videnovic A, Semenov I Chua-Adajar R, et al, &ldquo;Capecitabine-Induced Multifocal Leukoencephalopathy: A Report of Five Cases,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2005, 65(11):1792-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/16237130/pubmed\" id=\"16237130\" target=\"_blank\">",
"        16237130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Borstel R, O&rsquo;Neil J, and Bamat M, &ldquo;Vistonuridine: An Orally Administered, Life-Saving Antidote for 5-Fluorouracil (5FU) Overdose,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15S):9616 [abstract from 2009 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong M, Choo SP, and Tan EH, &ldquo;Travel Warning With Capecitabine,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2009, 20(7):2081.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/0/40967/abstract-text/19470576/pubmed\" id=\"19470576\" target=\"_blank\">",
"        19470576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8839 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-424AE69C25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40967=[""].join("\n");
var outline_f40_0_40967=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708655\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145140\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145141\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145191\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145144\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145145\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145146\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145147\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145192\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145116\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145101\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145120\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145119\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5583457\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2704106\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145189\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145123\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145105\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837645\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2706932\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145137\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145112\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145126\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145153\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145127\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145128\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145125\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145114\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145129\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145104\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145122\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8839\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8839|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/53/14165?source=related_link\">",
"      Capecitabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_0_40968="Overview of paraneoplastic syndromes of the nervous system";
var content_f40_0_40968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of paraneoplastic syndromes of the nervous system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/0/40968/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/0/40968/contributors\">",
"     Josep Dalmau, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/0/40968/contributors\">",
"     Myrna R Rosenfeld, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/0/40968/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/0/40968/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/0/40968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/0/40968/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/0/40968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic neurologic syndromes are a heterogeneous group of disorders caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy or side effects of cancer treatment. These syndromes may affect any part of the nervous system from cerebral cortex to neuromuscular junction and muscle (",
"    <a class=\"graphic graphic_table graphicRef50304 \" href=\"mobipreview.htm?30/58/31660\">",
"     table 1",
"    </a>",
"    ), either damaging one area (eg, Purkinje cell, presynaptic cholinergic synapses) or multiple areas (eg, encephalomyelitis).",
"   </p>",
"   <p>",
"    This topic provides an overview of the pathogenesis, diagnosis, and treatment of paraneoplastic disorders. Individual syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=see_link\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6583?source=see_link\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=see_link\">",
"     \"Paraneoplastic and autoimmune encephalitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26983?source=see_link\">",
"     \"Paraneoplastic cerebellar degeneration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42023?source=see_link\">",
"     \"Opsoclonus myoclonus ataxia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7239?source=see_link\">",
"     \"Paraneoplastic visual syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the pathogenesis of paraneoplastic neurologic syndromes is incompletely understood, immunologic factors are believed to be important because antibody and T-cell responses against nervous system antigens have been described for many of these disorders. The immunologic response is directed against shared antigens that are ectopically expressed by the tumor, but otherwise exclusively expressed by the nervous system (",
"    <a class=\"graphic graphic_picture graphicRef56327 \" href=\"mobipreview.htm?30/24/31110\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], or rarely by nervous system and testes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/3\">",
"     3",
"    </a>",
"    ]. For unknown reasons, the immune system identifies these antigens as foreign and mounts an immune attack against them. One report suggests that the immune system can mount a T-cell response to a normal protein when it is expressed in a cancer cell, suggesting that normal self antigens may be processed differently in cancer cells than in the normal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies can be detected in the serum and cerebrospinal fluid (CSF) of many, but not all, patients with paraneoplastic syndromes and, as will be described for the individual disorders, are highly suggestive of one or a restricted group of syndromes and types of tumors (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"mobipreview.htm?31/60/32717\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/2\">",
"     2",
"    </a>",
"    ]. Lung cancer (particularly small cell lung cancer, SCLC) accounts for a disproportionate number and variety of paraneoplastic syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/5\">",
"     5",
"    </a>",
"    ], the range of which is shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef51311 \" href=\"mobipreview.htm?29/61/30685\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    To date, antibodies with a direct pathogenic effect on the target neuronal or neuromuscular antigens have only been found in a few disorders of the peripheral nerve or neuromuscular junction. These antibodies are not truly paraneoplastic antibodies, as they can also occur in the non-paraneoplastic setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/6\">",
"     6",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       P/Q",
"      </span>",
"      type voltage-gated calcium channel antibodies in the Lambert-Eaton myasthenic syndrome (LEMS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acetylcholine receptor antibodies in myasthenia gravis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      NMDA receptor (NR1) antibodies in anti-NMDAR encephalitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      AMPA receptor",
"      <span class=\"nowrap\">",
"       (GluR1/2)",
"      </span>",
"      antibodies in a subgroup of limbic encephalitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ganglionic acetylcholine receptor antibodies in autonomic neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Recoverin antibodies in carcinoma associated retinopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Autoantibodies may also play an important role in other paraneoplastic syndromes such as the stiff person syndrome and dermatomyositis. &nbsp;The role of autoantibodies in the pathogenesis of these disorders is the rationale for the recent use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a pathogenic role of paraneoplastic antibodies has not been proven, their presence indicates the paraneoplastic nature of a neurologic disorder, and in many cases, can narrow the search for an occult tumor to a few organs (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"mobipreview.htm?31/60/32717\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is evidence that some paraneoplastic neurologic syndromes without an identifiable tumor may result from immune-mediated eradication of tumor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/14\">",
"     14",
"    </a>",
"    ]. In keeping with this hypothesis, some reports suggest a more limited disease distribution and better outcome among patients with SCLC who develop immunity to paraneoplastic antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. However, review of most large series of patients demonstrates that the oncologic outcome of patients with antibody-associated paraneoplastic syndromes does not significantly differ from that of patients who do not have the antibodies or a paraneoplastic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/5,18-22\">",
"     5,18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cell-mediated immunity also appears to play an important role in paraneoplastic neurologic disorders. T-cell responses directed against the same tumor antigens can be demonstrated in some patients, although the relative contribution of cellular and humoral immunity to the clinical and pathologic manifestations is an unresolved issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on those neurologic syndromes that are associated with paraneoplastic antibodies. There are also nonimmunologic mechanisms that can be involved in paraneoplastic neurologic syndromes and are discussed elsewhere. These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic abnormalities due to tumoral secretion of hormones or cytokines (eg, hyponatremia due to antidiuretic hormone, hypercalcemia due to parathyroid hormone-related protein, or hypoglycemia due to insulin-like growth factor-II). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=see_link\">",
"       \"Hypercalcemia of malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=see_link\">",
"       \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Competition between the tumor and the nervous system for a substrate (eg, carcinoid tumors and tryptophan). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=see_link\">",
"       \"Clinical features of the carcinoid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The synthesis by the tumor of immunoglobulins that react with the peripheral nervous system (eg, a distal, symmetric, and slowly progressive sensorimotor peripheral neuropathy in Waldenstrom's macroglobulinemia) and antibodies against myelin-associated glycoprotein (MAG). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic disorders (PND) are more frequent than previously considered, with an incidence that varies with the neurologic syndrome and type of tumor. The more common syndromes are Lambert-Eaton myasthenic syndrome (LEMS), which affects approximately 3 percent of patients with small-cell lung cancer (SCLC), and myasthenia gravis, which affects 15 percent of all patients with thymoma. For other solid tumors, the incidence of paraneoplastic neurologic syndromes is far less than 1 percent in most tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paraneoplastic peripheral neuropathies affect 5 to 15 percent of patients with plasma cell dyscrasias associated with malignant monoclonal gammopathies. More than 50 percent of patients with the rare osteosclerotic form of myeloma develop a predominantly motor paraneoplastic peripheral neuropathy. Patients with all forms of myeloma, but usually the osteosclerotic type, can develop a severe, symmetric, sensorimotor neuropathy with muscle atrophy in association with the POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8474?source=see_link\">",
"     \"Clinical presentation and management of thymoma and thymic carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=see_link\">",
"     \"POEMS syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERAL DIAGNOSTIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many paraneoplastic syndromes develop in the early stages of cancer, and the presence of a tumor or tumor recurrence can be difficult to demonstrate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the challenges that can arise in diagnosing paraneoplastic syndromes of the nervous system, an international panel of neurologists has worked to establish more rigorous diagnostic criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/28\">",
"     28",
"    </a>",
"    ]. These criteria divide patients with suspected paraneoplastic syndromes into \"definite\" and \"possible\" categories as follows.",
"   </p>",
"   <p>",
"    Definite syndromes include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A \"classical\" syndrome and cancer that develops within five years of diagnosis of the neurologic disorder. A classical syndrome is defined as a neurologic syndrome that is frequently associated with cancer. Classical syndromes include encephalomyelitis, limbic encephalitis, subacute cerebellar degeneration, opsoclonus-myoclonus, subacute sensory neuronopathy, chronic gastrointestinal pseudoobstruction, Lambert-Eaton myasthenic syndrome, and dermatomyositis.",
"     </li>",
"     <li>",
"      A nonclassical syndrome that resolves or significantly improves after cancer treatment without concomitant immunotherapy, provided that the syndrome is not susceptible to spontaneous remission.",
"     </li>",
"     <li>",
"      A nonclassical syndrome with paraneoplastic antibodies and cancer that develops within five years of the diagnosis of the neurologic disorder.",
"     </li>",
"     <li>",
"      A neurologic syndrome (classical or not) with \"well-characterized\" paraneoplastic antibodies and no cancer. These well-characterized antibodies include anti-Hu, CV2, Ri, Ma2, or amphiphysin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible syndromes include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A classical syndrome as defined above, no paraneoplastic antibodies, no cancer, but at high risk to have an underlying tumor.",
"     </li>",
"     <li>",
"      A neurologic syndrome (classical or not) with partially characterized paraneoplastic antibodies (eg, not the well-characterized antibodies described above) and no cancer.",
"     </li>",
"     <li>",
"      A nonclassical syndrome, no paraneoplastic antibodies, and cancer present within two years of diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antibody screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having a paraneoplastic neurologic syndrome should be examined for paraneoplastic antibodies in their serum. In some patients, the CSF reveals antibodies undetected in serum, but this is relatively rare and appears to affect only a few antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Lumbar puncture'",
"    </a>",
"    below.) Well-characterized paraneoplastic antibodies are those directed against antigens whose molecular identity is known or that have been identified by several investigators, while partially-characterized antibodies are those whose target antigens are unknown or require further analysis (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"mobipreview.htm?31/60/32717\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important tenets of antibody screening include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While some antibodies such as",
"      <span class=\"nowrap\">",
"       P/Q",
"      </span>",
"      type voltage-gated calcium channel antibodies or acetylcholine receptor antibodies associate with specific disorders, they do not differentiate between paraneoplastic and non-paraneoplastic cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/11,32,33\">",
"       11,32,33",
"      </a>",
"      ]. As an example, antibodies to GAD or amphiphysin have been reported in association with the stiff-person syndrome, but the majority of patients with antibodies to GAD do not have cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/665?source=see_link\">",
"       \"Stiff-person syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The serum of cancer patients without paraneoplastic neurologic syndromes may contain paraneoplastic antibodies, although the titers are usually lower [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/15,36,37\">",
"       15,36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Different antibodies can be associated with the same paraneoplastic neurologic syndrome and conversely, the same antibody may be associated with different syndromes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/38-40\">",
"       38-40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several paraneoplastic antibodies may co-occur in the same patient, particularly if the underlying tumor is SCLC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, well-characterized paraneoplastic antibodies are sometimes found in patients with cancer but without neurologic symptoms and patients with neurologic disorders without an identifiable cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/6\">",
"     6",
"    </a>",
"    ]. However, well-characterized paraneoplastic antibodies (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"mobipreview.htm?31/60/32717\">",
"     table 2",
"    </a>",
"    ) rarely, if ever, occur in normal individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. The presence of such antibodies should demand a careful search for an underlying neoplasm.",
"   </p>",
"   <p>",
"    Testing for paraneoplastic antibodies can facilitate the recognition of the simultaneous occurrence of two or sometimes three paraneoplastic neurologic syndromes in one patient. As an example, patients with SCLC and paraneoplastic cerebellar degeneration develop LEMS more frequently than expected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/44\">",
"     44",
"    </a>",
"    ]. Since the development of both disorders is highly disabling, and LEMS usually responds to treatment, all patients with SCLC who develop paraneoplastic cerebellar symptoms should be examined for LEMS. In almost all patients with LEMS, lower extremity reflexes are absent; sometimes they reappear after exercise. Another association is the development of LEMS in about 6 percent of patients with anti-Hu associated paraneoplastic encephalomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=see_link\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis may be particularly difficult in patients with known cancer and neurologic symptoms in whom paraneoplastic antibodies cannot be detected. Absence of these antibodies does not exclude a paraneoplastic syndrome; however, the presumptive diagnosis requires the absence of the metastatic and nonmetastatic complications noted above.",
"   </p>",
"   <p>",
"    In the absence of characteristic antibodies in the serum, specific diagnostic tests may be helpful for some paraneoplastic syndromes:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging can assist in the diagnosis of limbic encephalitis because the medial temporal lobes, the site of major pathology, often show increased signal on FLAIR images and occasionally areas of contrast enhancement. Patients with paraneoplastic cerebellar degeneration may develop signs of atrophy detectable by magnetic resonance imaging (MRI) several months after the onset of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]. For most paraneoplastic syndromes, however, neuroimaging studies are normal or nonspecific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     PET",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography of the brain using fluorodeoxyglucose (FDG-PET) will occasionally identify hypermetabolism of the medial temporal lobe(s) in patients with limbic encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/47\">",
"     47",
"    </a>",
"    ] or of the cerebellum in patients with paraneoplastic cerebellar degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although detection of paraneoplastic antibodies in the cerebrospinal fluid (CSF) confirms that the disorder is paraneoplastic, in our experience these antibodies are usually present in the serum as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/31\">",
"     31",
"    </a>",
"    ]. Exceptions include some patients with anti-Tr antibodies and patients with antibodies to antigens expressed in the cell membrane of neurons of the neuropil of hippocampus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. CSF examination can assist in making the diagnosis of paraneoplastic syndromes in two other ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of negative cytology for malignant cells and the absence of meningeal enhancement on MRI can reasonably exclude leptomeningeal carcinomatosis.",
"     </li>",
"     <li>",
"      Inflammatory changes (eg, pleocytosis, intrathecal synthesis of IgG, oligoclonal bands) can support the presence of an inflammatory or immune-mediated neurologic disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Electrophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some paraneoplastic syndromes of the peripheral nervous system are associated with characteristic electrophysiologic findings. These include LEMS, myasthenia gravis, neuromyotonia, and dermatomyositis. However, these findings are also present when the neurologic syndrome is not associated with a tumor. Nevertheless, electrophysiologic findings that confirm the underlying syndrome may still be helpful by directing the search for the neoplasm to specific organs (eg, lung with LEMS, and thymus with myasthenia gravis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Occult malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While paraneoplastic syndromes are most often diagnosed in the setting of a known malignancy, it is not uncommon for a paraneoplastic disorder develop before a cancer is identified.",
"   </p>",
"   <p>",
"    The clinical syndrome and identification of certain paraneoplastic antibodies may suggest a specific underlying tumor and direct investigations (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"mobipreview.htm?31/60/32717\">",
"     table 2",
"    </a>",
"    ). In most other instances, the tumor is revealed by computed tomograph (CT) of the chest, abdomen, and pelvis. Additional tests, such as mammogram, breast MRI, or ultrasound of the pelvis or testes, are ordered when suggested by the clinical syndrome and identification of certain paraneoplastic antibodies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of other risk factors.",
"   </p>",
"   <p>",
"    Whole body fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in demonstrating occult neoplasms or small metastatic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. In one case series of 104 patients, sensitivity and specificity of FDG-PET were 80 and 67 percent, compared to 30 and 71 percent for CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/53\">",
"     53",
"    </a>",
"    ]. Results from another small study suggest that FDG-PET combined with CT scanning increases sensitivity and accuracy of tumor diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A negative",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan does not rule out underlying cancer; use of other imaging modalities (eg, magnetic resonance imaging, ultrasound)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repeating",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan after a several-month interval can be fruitful. A 2010 taskforce recommended repeat screening in three to six months after an initial negative evaluation, followed by screening every six months up until four years, if testing remains unrevealing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/55\">",
"     55",
"    </a>",
"    ]. In Lambert-Easton myasthenic syndrome, screening for two years is sufficient. Also, if an identified cancer is not consistent with the paraneoplastic syndrome or the identified antibody, continued search for another neoplasm should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the majority of neurologic paraneoplastic syndromes are immune-mediated, two general approaches to therapy have been tried: removal of the antigen source by treatment of the underlying tumors, and suppression of the immune response. Immunosuppression is beneficial for some conditions, such as the Lambert-Eaton myasthenic syndrome (LEMS) and myasthenia gravis, in which plasma exchange or intravenous immune globulin (IVIG) (eg, 0.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    daily for five days) is usually effective in suppressing the immune response and improving neurologic status, at least in the short term. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=see_link&amp;anchor=H14#H14\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\", section on 'Lambert-Eaton myasthenic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most patients with paraneoplastic peripheral neuropathies do not have paraneoplastic antibodies, there is often evidence of an immune-mediated etiology, such as cerebrospinal fluid (CSF) pleocytosis, increased CSF proteins, or the presence of inflammatory infiltrates on nerve biopsy. For these disorders, and particularly those with predominant demyelinating features, plasmapheresis, IVIG, and immunosuppression can be effective. In those disorders that are probably antibody-mediated, specific anti-B cell therapy using antibodies such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    could be considered. Case reports and small series describe efficacy of rituximab in pediatric opsoclonus myoclonus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/57\">",
"     57",
"    </a>",
"    ], stiff person syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/58\">",
"     58",
"    </a>",
"    ], dermatomyositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/59\">",
"     59",
"    </a>",
"    ], anti-Yo positive paraneoplastic cerebellar degeneration, and anti-Hu antibody-associated encephalomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For other paraneoplastic neurologic syndromes, there is evidence that prompt oncologic treatment and immunotherapy (immunomodulation, immunosuppression) can be beneficial, especially if instituted during the time of symptom progression rather than after deficits have been fully established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. The failure of the neurologic syndrome to respond to treatment may be due to irreversible neuronal damage that occurred before the diagnosis was made and treatment begun. Rare patients may develop a second paraneoplastic syndrome, after recovering or stabilizing from the first. In one case series of eight such patients, the second paraneoplastic syndrome revealed cancer relapse in five and a second cancer in one patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40968/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the combination of oncologic and immunosuppressive therapies may have significant toxicity, immunologic treatments should be stratified accordingly. For patients with progressive neurologic symptoms who are receiving chemotherapy, immunosuppression or immunomodulation may include oral or intravenous corticosteroids and intravenous immunoglobulins. Most reports suggest that plasma exchange is rarely effective. Patients with progressive neurologic symptoms who are not receiving chemotherapy should be considered for more aggressive immunosuppression that may include oral or intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A general overview of the approach to treatment is shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef54804 \" href=\"mobipreview.htm?7/59/8125\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic neurologic syndromes are a heterogeneous group of disorders caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment. These syndromes may affect any part of the nervous system from cerebral cortex to neuromuscular junction and muscle (",
"    <a class=\"graphic graphic_table graphicRef50304 \" href=\"mobipreview.htm?30/58/31660\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paraneoplastic neurologic syndromes are believed to result when an immunologic response is directed against shared antigens that are ectopically expressed by the tumor, but otherwise predominantly expressed by the nervous system. Antibodies can be detected in the serum and cerebrospinal fluid (CSF) of many, but not all, patients with paraneoplastic syndromes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients suspected of having a paraneoplastic neurologic syndrome should be examined for paraneoplastic antibodies in their serum (",
"      <a class=\"graphic graphic_table graphicRef77919 \" href=\"mobipreview.htm?31/60/32717\">",
"       table 2",
"      </a>",
"      ). However, important caveats include that:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low levels of some paraneoplastic antibodies may be seen in the serum of cancer patients without paraneoplastic syndromes.",
"     </li>",
"     <li>",
"      Well-characterized paraneoplastic antibodies rarely, if ever, occur in normal individuals. The presence of such antibodies should demand a careful search for an underlying neoplasm.",
"     </li>",
"     <li>",
"      Some, but not all, paraneoplastic antibodies may be associated with different neurologic syndromes and the same neurologic syndrome may be associated with different paraneoplastic antibodies. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Antibody screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuroimaging studies, lumbar puncture, and electrophysiology tests can be helpful in characterizing the neurologic syndrome. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The paraneoplastic syndrome may precede the diagnosis of underlying malignancy. In such cases, the clinical syndrome and identification of certain paraneoplastic antibodies may suggest a specific underlying tumor and direct investigations (",
"      <a class=\"graphic graphic_table graphicRef77919 \" href=\"mobipreview.htm?31/60/32717\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Occult malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two general approaches to treatment include: removal of the antigen source by treatment of the underlying tumors, and suppression of the immune response. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment and prognosis overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/1\">",
"      Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 1999; 9:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/2\">",
"      Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 1992; 141:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/3\">",
"      Rosenfeld MR, Eichen JG, Wade DF, et al. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/4\">",
"      Savage PA, Vosseller K, Kang C, et al. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 2008; 319:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/5\">",
"      Graus F, Keime-Guibert F, Re&ntilde;e R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/6\">",
"      Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010; 257:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/7\">",
"      Lang B, Newsom-Davis J, Wray D, et al. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981; 2:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/8\">",
"      Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/9\">",
"      Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/10\">",
"      Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/11\">",
"      Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000; 343:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/12\">",
"      Ohguro H, Nakazawa M. Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol 2002; 514:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/13\">",
"      Dalakas MC. Invited article: inhibition of B cell functions: implications for neurology. Neurology 2008; 70:2252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/14\">",
"      Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/15\">",
"      Graus F, Dalmou J, Re&ntilde;&eacute; R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15:2866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/16\">",
"      Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999; 353:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/17\">",
"      Wirtz PW, Lang B, Graus F, et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005; 164:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/18\">",
"      Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/19\">",
"      Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/20\">",
"      Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/21\">",
"      Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/22\">",
"      Monstad SE, Drivsholm L, Storstein A, et al. Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 2004; 22:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/23\">",
"      Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000; 47:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/24\">",
"      Benyahia B, Liblau R, Merle-B&eacute;ral H, et al. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 1999; 45:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/25\">",
"      Tanaka M, Tanaka K, Shinozawa K, et al. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 1998; 161:88.",
"     </a>",
"    </li>",
"    <li>",
"     Posner JB. Neurologic Complications of Cancer, FA Davis, Philadelphia 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/27\">",
"      Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve 2000; 23:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/28\">",
"      Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/29\">",
"      Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/30\">",
"      Vitaliani R, Mason W, Ances B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005; 58:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/31\">",
"      McKeon A, Pittock SJ, Lennon VA. CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology 2011; 76:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/32\">",
"      Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995; 58:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/33\">",
"      Pozo-Rosich P, Clover L, Saiz A, et al. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003; 54:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/34\">",
"      Solimena M, Folli F, Aparisi R, et al. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/35\">",
"      Folli F, Solimena M, Cofiell R, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993; 328:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/36\">",
"      Drlicek M, Bianchi G, Bogliun G, et al. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol 1997; 244:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/37\">",
"      Dalmau J, Furneaux HM, Gralla RJ, et al. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann Neurol 1990; 27:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/38\">",
"      Bataller L, Wade DF, Graus F, et al. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004; 62:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/39\">",
"      Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004; 56:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/40\">",
"      McKeon A, Tracy JA, Pittock SJ, et al. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol 2011; 68:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/41\">",
"      Knudsen A, Monstad SE, D&oslash;rum A, et al. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother 2006; 55:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/42\">",
"      Monstad SE, Storstein A, D&oslash;rum A, et al. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 2006; 144:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/43\">",
"      McKeon A, Lennon VA, Lachance DH, et al. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol 2009; 66:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/44\">",
"      Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120 ( Pt 8):1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/45\">",
"      Voltz R, Carpentier AF, Rosenfeld MR, et al. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. Muscle Nerve 1999; 22:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/46\">",
"      Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/47\">",
"      Basu S, Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 2008; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/48\">",
"      Choi KD, Kim JS, Park SH, et al. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 2006; 77:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/49\">",
"      Psimaras D, Carpentier AF, Rossi C, PNS Euronetwork. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 2010; 81:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/50\">",
"      Rees JH, Hain SF, Johnson MR, et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001; 124:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/51\">",
"      Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004; 127:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/52\">",
"      McKeon A, Apiwattanakul M, Lachance DH, et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol 2010; 67:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/53\">",
"      Patel RR, Subramaniam RM, Mandrekar JN, et al. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc 2008; 83:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/54\">",
"      Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004; 63:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/55\">",
"      Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/56\">",
"      Leyhe T, Sch&uuml;le R, Schw&auml;rzler F, et al. Second primary tumor in anti-Ma1/2-positive paraneoplastic limbic encephalitis. J Neurooncol 2006; 78:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/57\">",
"      Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006; 28:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/58\">",
"      Buckley C, Vincent A. Autoimmune channelopathies. Nat Clin Pract Neurol 2005; 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/59\">",
"      Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/60\">",
"      Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/61\">",
"      Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/62\">",
"      Vernino S, O'Neill BP, Marks RS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol 2004; 6:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/63\">",
"      Rosenfeld MR, Dalmau J. Current Therapies for Paraneoplastic Neurologic Syndromes. Curr Treat Options Neurol 2003; 5:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40968/abstract/64\">",
"      Ducray F, Graus F, Vigliani MC, et al. Delayed onset of a second paraneoplastic neurological syndrome in eight patients. J Neurol Neurosurg Psychiatry 2010; 81:937.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5188 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40968=[""].join("\n");
var outline_f40_0_40968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERAL DIAGNOSTIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antibody screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - PET",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Electrophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Occult malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT AND PROGNOSIS OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5188\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5188|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/24/31110\" title=\"picture 1\">",
"      Reactivity of paraneoplastic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5188|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/58/31660\" title=\"table 1\">",
"      Paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/60/32717\" title=\"table 2\">",
"      Paraneoplastic antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/61/30685\" title=\"table 3\">",
"      Paraneoplastic syndromes associated with lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/59/8125\" title=\"table 4\">",
"      Treatment of paraneoplastic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8474?source=related_link\">",
"      Clinical presentation and management of thymoma and thymic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=related_link\">",
"      Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42023?source=related_link\">",
"      Opsoclonus myoclonus ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=related_link\">",
"      POEMS syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26983?source=related_link\">",
"      Paraneoplastic cerebellar degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6583?source=related_link\">",
"      Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7239?source=related_link\">",
"      Paraneoplastic visual syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/665?source=related_link\">",
"      Stiff-person syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_0_40969="Causes of primary adrenal insufficiency (Addison's disease)";
var content_f40_0_40969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of primary adrenal insufficiency (Addison's disease)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/0/40969/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/0/40969/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/0/40969/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/0/40969/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/0/40969/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/0/40969/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/0/40969/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When Thomas Addison described the disease that now bears his name [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/1\">",
"     1",
"    </a>",
"    ], bilateral adrenal destruction by tuberculosis was its most common cause. Now tuberculosis accounts for only 7 to 20 percent of cases; autoimmune disease is responsible for 70 to 90 percent, with the remainder being caused by other infectious diseases, replacement by metastatic cancer or lymphoma, adrenal hemorrhage or infarction, or drugs (",
"    <a class=\"graphic graphic_table graphicRef52048 \" href=\"mobipreview.htm?16/57/17308\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Disseminated tuberculous or fungal infections are still a major cause of adrenal insufficiency in populations with a high prevalence of these diseases, but as tuberculosis has been better controlled, the overall incidence of Addison's disease has decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/6\">",
"     6",
"    </a>",
"    ]. The prevalence of Addison's disease in Western countries has been estimated at 35 to 60 per million, but three studies indicate it may be as high as 144 per million [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the major causes of primary adrenal insufficiency. Rarer causes are discussed separately. The rarer diseases, such as adrenal",
"    <span class=\"nowrap\">",
"     leukodystrophy/adrenal",
"    </span>",
"    myeloneuropathy, are mostly inherited disorders that present in infancy or childhood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33673?source=see_link\">",
"     \"Adrenoleukodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12408?source=see_link\">",
"     \"Unusual causes of adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE ADRENALITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925578\">",
"    <span class=\"h2\">",
"     Destruction of adrenal cortex",
"    </span>",
"    &nbsp;&mdash;&nbsp;What long was termed \"idiopathic\" primary adrenal insufficiency is the result of an autoimmune process that destroys the adrenal cortex. There is evidence of both humoral and cell-mediated immune mechanisms directed at the adrenal cortex, often associated with autoimmune destruction of other endocrine glands (referred to as polyglandular autoimmune syndromes). Antibodies that react with several steroidogenic enzymes (most often 21-hydroxylase) and all three zones of the adrenal cortex are present in the serum of up to 86 percent of patients with autoimmune primary adrenal insufficiency (anti-21-OHase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/9\">",
"     9",
"    </a>",
"    ]), but only rarely in patients with other causes of adrenal insufficiency, or in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, up to 10 percent of first-degree relatives of patients with autoimmune primary adrenal insufficiency express these antibodies and have an increased risk of developing adrenal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9896?source=see_link\">",
"     \"Pathogenesis of autoimmune adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925571\">",
"    <span class=\"h2\">",
"     Sex differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with autoimmune adrenal insufficiency as part of one of the polyglandular autoimmune syndromes are predominately female (70 percent). In contrast, patients with isolated autoimmune adrenal insufficiency are predominately male (71 percent) during the first two decades of life, are equally male and female in the third decade, and are predominately female (81 percent) thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/11\">",
"     11",
"    </a>",
"    ]. The explanation for these sex differences is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925564\">",
"    <span class=\"h2\">",
"     Early findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first evidence of autoimmune adrenal insufficiency is usually an increase in plasma renin activity in association with a normal or low serum aldosterone concentration, suggesting that the zona glomerulosa is involved initially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Several months to years later, zona fasciculata dysfunction becomes evident, first by a decreasing serum cortisol response to corticotropin (ACTH) stimulation, later by increased basal serum ACTH concentrations, and finally by decreasing basal serum cortisol concentrations and symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study suggests that a rise in serum ACTH is the best predictor of the subsequent development of adrenal insufficiency in patients with 21-hydroxylase autoantibodies. This was illustrated in a report of 87 such individuals (excluding polyglandular autoimmune syndrome type I patients), who were followed during the two years preceding the onset of adrenal insufficiency. Seven developed adrenal insufficiency while 80 did not. When compared to non-progressors, those who progressed to adrenal insufficiency were more likely to have an elevated serum ACTH, but there were no differences in plasma renin activity, or peak cortisol response to exogenous ACTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925585\">",
"    <span class=\"h2\">",
"     Other endocrine disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 to 65 percent of patients with autoimmune adrenal insufficiency have one or more other autoimmune endocrine disorders (",
"    <a class=\"graphic graphic_table graphicRef69574 \" href=\"mobipreview.htm?34/13/35035\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/2,3,9,16-19\">",
"     2,3,9,16-19",
"    </a>",
"    ]. On the other hand, patients with the more common autoimmune endocrine disorders, such as type 1 (insulin-dependent) diabetes mellitus, chronic autoimmune thyroiditis, or Graves' disease, rarely develop adrenal insufficiency. In one report, as an example, 11 of 629 patients (1.7 percent) with type 1 diabetes but none of 239 normal subjects had antibodies directed against 21-hydroxylase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/20\">",
"     20",
"    </a>",
"    ]. Three of the eight patients with anti-21-hydroxylaseantibodies had adrenal insufficiency. In another study, only 1 of 114 children with type 1 diabetes and none of 35 children with autoimmune thyroiditis tested positive for anti-adrenal antibodies measured by immunofluorescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, about 80 percent of patients with diabetes mellitus associated with the DQ8 HLA allele who also have the DRB*0404 HLA allele and autoantibodies against 21-hydroxylase develop adrenal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In another report of 38 patients with type 1 diabetes who also had antibodies directed against 21-hydroxylase, those who were homozygous for MICA5.1 (an MHC class I related molecule located between tumor necrosis factor-alpha and HLA-B) were at higher risk for developing adrenal insufficiency than those without homozygosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adrenal insufficiency is easily diagnosed and treated and is potentially lethal if unrecognized; this has led some investigators to recommend screening for this disorder in all patients with type 1 diabetes. Nevertheless, we do not believe that testing this large patient population is warranted, given the approximately 1 percent prevalence of subnormal responses to ACTH in these patients.",
"   </p>",
"   <p>",
"    Patients with celiac disease had an 11-fold increased risk for adrenal insufficiency in a Swedish study, and 6 of 76 patients with adrenal insufficiency had celiac disease in a Norwegian study, suggesting that patients with either disorder should be evaluated for the other as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of autoimmune adrenal insufficiency with other autoimmune endocrine disorders is referred to as the polyglandular autoimmune syndromes types I and II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. The genetics and pathogenesis of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9896?source=see_link\">",
"     \"Pathogenesis of autoimmune adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Polyglandular autoimmune syndrome type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyglandular autoimmune syndrome type I (APS1), also referred to as the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, is a rare autosomal recessive disorder in which females are affected slightly more frequently than males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. It is most common among Finns, Sardinians, and Iranian Jews; sporadic cases also have been identified elsewhere, including most European countries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9896?source=see_link\">",
"     \"Pathogenesis of autoimmune adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925657\">",
"    <span class=\"h3\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;APECED appears to be due to mutations in the so-called autoimmune regulator (AIRE) gene on chromosome 21q22.3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. The AIRE gene product is expressed in the thymus, lymph nodes, pancreas, adrenal cortex, and fetal liver; it appears to be a nuclear transcription factor, but its exact mechanism in causing the syndrome is unclear. One theory is that it is important in the selection and generation of regulatory T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. The predominant gene mutation differs in different patient populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/33,34,38,39\">",
"     33,34,38,39",
"    </a>",
"    ]. There is no apparent correlation between specific gene mutations and phenotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925664\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoparathyroidism or chronic mucocutaneous candidiasis is usually the first manifestation, characteristically appearing during childhood or early adolescence, always by the early twenties (",
"      <a class=\"graphic graphic_table graphicRef67520 \" href=\"mobipreview.htm?9/25/9629\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/11,27-29\">",
"       11,27-29",
"      </a>",
"      ]. The hypoparathyroidism may [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/40,41\">",
"       40,41",
"      </a>",
"      ] or may not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/42\">",
"       42",
"      </a>",
"      ] occur in association with antiparathyroid gland antibodies that are directed against the calcium-sensing receptor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=see_link&amp;anchor=H9#H9\">",
"       \"Etiology of hypocalcemia in adults\", section on 'Autoimmune'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The candidiasis almost always involves the mouth, although it may involve just the nail beds or be more extensive (",
"      <a class=\"graphic graphic_picture graphicRef64895 \" href=\"mobipreview.htm?10/1/10258\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/27\">",
"       27",
"      </a>",
"      ]. It is chronic or recurrent, and is resistant to conventional therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of Candida infections\", section on 'Chronic mucocutaneous candidiasis'",
"      </a>",
"      .) Oral mucous squamous cell carcinoma has been rarely reported in association with the candidiasis of APECED [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adrenal insufficiency usually develops later, at age 10 to 15 years. The antigen targets are adrenal enzymes including P450scc (side-chain cleavage enzyme), P450c17 (17-alpha-hydroxylase), and P450c21 (21-hydroxylase) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/44\">",
"       44",
"      </a>",
"      ]. The presence of adrenal autoantibodies has a high (92 percent) positive predictive value for development of adrenal insufficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/14,36\">",
"       14,36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9896?source=see_link&amp;anchor=H4#H4\">",
"       \"Pathogenesis of autoimmune adrenal insufficiency\", section on 'Antigen targets'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary hypogonadism occurs in about 60 percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23976?source=see_link\">",
"       \"Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malabsorption and other gastrointestinal disorders occur in about 25 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/45,46\">",
"       45,46",
"      </a>",
"      ], of whom 90 percent have autoantibodies to tryptophan hydroxylase, an intestinal antigen. Only one-third of patients without gastrointestinal disorders have these autoantibodies. One report described a patient with severe malabsorption syndrome due to a deficiency of cholecystokinin-producing enteroendocrine cells in the mucosa of the proximal small bowel [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one series of 68 Finnish patients, approximately 50 percent of patients developed the triad of candidiasis, hypoparathyroidism, and adrenal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/27\">",
"     27",
"    </a>",
"    ]. Diabetes mellitus and chronic autoimmune thyroiditis are uncommon. Graves' disease is not associated with this disorder (",
"    <a class=\"graphic graphic_table graphicRef67520 \" href=\"mobipreview.htm?9/25/9629\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the patient series noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/27\">",
"     27",
"    </a>",
"    ], the incidence of various manifestations was different from that reported in other smaller series and reviews of the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/27\">",
"     27",
"    </a>",
"    ]. These differences from previous reports may reflect a variant form of the disorder or more thorough examination of affected patients. As an example, diabetes mellitus was 12 times more prevalent, and manifestations of ectodermal dysplasia, including dental enamel hypoplasia, pitted dystrophy of the nails, keratopathy, and calcified plaques on the tympanic membranes, were present in one-third to two-thirds of the patients. In a report of 62 Finnish and seven Swedish patients, 17 percent had autoimmune chronic active hepatitis in association with antibodies directed against aromatic l-amino acid decarboxylase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/48\">",
"     48",
"    </a>",
"    ]. The use of autoantibodies to predict disease manifestations is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9896?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of autoimmune adrenal insufficiency\", section on 'Humoral immunity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The variable clinical presentation and progression are presumably due to environmental factors and genetic factors other than AIRE gene mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Polyglandular autoimmune syndrome type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type II syndrome (APS2) is much more prevalent than the type I syndrome and primary adrenal insufficiency is its principal manifestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/28,29,49\">",
"     28,29,49",
"    </a>",
"    ]. Antibodies to steroidogenic enzymes also are present in this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/44\">",
"     44",
"    </a>",
"    ]. Autoimmune thyroid disease, usually chronic autoimmune thyroiditis but occasionally Graves' disease, and type 1 diabetes mellitus are also common (",
"    <a class=\"graphic graphic_table graphicRef69574 \" href=\"mobipreview.htm?34/13/35035\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67520 \" href=\"mobipreview.htm?9/25/9629\">",
"     table 3",
"    </a>",
"    ). The type II syndrome with primary adrenal insufficiency and autoimmune thyroid disease was formerly referred to as \"Schmidt's syndrome.\" Patients with autoimmune thyroid disease or diabetes mellitus who have adrenal autoantibodies but do not yet have adrenal insufficiency and relatives who have one or more components of the syndrome should also be considered to have the disorder.",
"   </p>",
"   <p>",
"    Approximately one-half of cases are familial and several modes of inheritance (autosomal recessive, autosomal dominant, and polygenic) have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/11,28,29\">",
"     11,28,29",
"    </a>",
"    ]. Women are affected up to three times more often than men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/49\">",
"     49",
"    </a>",
"    ]. The age of onset ranges from childhood to late adulthood, with most cases occurring between age 20 and 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/11,18,28,49\">",
"     11,18,28,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1925680\">",
"    <span class=\"h3\">",
"     Affected endocrine organs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenal insufficiency is the initial manifestation in about 50 percent of patients, occurs simultaneously with autoimmune thyroid disease or diabetes mellitus in about 20 percent, and follows them in about 30 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/11,18,28\">",
"       11,18,28",
"      </a>",
"      ]. In one series, however, adrenal insufficiency was the initial manifestation in only 19 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary hypogonadism can occur first and, as in type I polyglandular autoimmune syndrome, ovarian failure is more frequent than testicular failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/18,28,29\">",
"       18,28,29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23976?source=see_link\">",
"       \"Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypoparathyroidism does",
"      <strong>",
"       not",
"      </strong>",
"      occur in this disorder, and alopecia and pernicious anemia are much less frequent than in the type I syndrome.",
"     </li>",
"     <li>",
"      Hypopituitarism due to autoimmune hypophysitis, preferentially causing ACTH deficiency, can occur alone or in combination with thyrotropin or, rarely, growth hormone deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=see_link\">",
"       \"Causes of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other nonendocrine autoimmune disorders, such as vitiligo, myasthenia gravis, thrombocytopenic purpura, Sj&ouml;gren's syndrome, rheumatoid arthritis, and primary antiphospholipid syndrome, occur occasionally [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/28,29,51\">",
"       28,29,51",
"      </a>",
"      ], as does serositis with pericardial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pleural involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/52\">",
"       52",
"      </a>",
"      ]. Patients with vitiligo, as an example, can have autoantibodies to tyrosinase, an enzyme involved in the synthesis of melanin, tyrosinase-related proteins, or to a melanocyte-specific protein called Pmel17 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INFECTIOUS ADRENALITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of infectious agents can infect the adrenal gland and lead to adrenal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis can destroy the adrenal glands. Tuberculous adrenalitis results from hematogenous spread from active infection elsewhere in the body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/54\">",
"     54",
"    </a>",
"    ]. Extraadrenal tuberculosis is usually evident, but may be clinically latent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\", section on 'Genitourinary and adrenal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adrenal destruction is gradual, with the medulla being destroyed more often than the cortex, for unknown reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/54\">",
"     54",
"    </a>",
"    ]. Antiadrenal autoantibodies are",
"    <strong>",
"     not",
"    </strong>",
"    present in serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/56\">",
"     56",
"    </a>",
"    ]. The adrenal glands are usually enlarged by inflammatory cell infiltration of the cortex and granulomas early in the disease; the increase in size can be detected by computed tomography (CT) or magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/55,57,58\">",
"     55,57,58",
"    </a>",
"    ]. Caseous nodules and fibrosis then gradually replace the adrenal gland tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/55\">",
"     55",
"    </a>",
"    ], so that after about two years the adrenals become normal or small in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/55,57-59\">",
"     55,57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenal calcifications can be seen radiographically in 50 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/55,57,59\">",
"       55,57,59",
"      </a>",
"      ]. However, the absence of enlarged or calcified adrenal glands does not rule out tuberculosis as the cause of adrenal insufficiency.",
"     </li>",
"     <li>",
"      Recovery of normal adrenal function may occur after effective antituberculous therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/60\">",
"       60",
"      </a>",
"      ], but usually does not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The adrenal glands may be enlarged in patients with pulmonary tuberculosis even when adrenal function is normal. Adrenal size becomes smaller after successful treatment of the tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disseminated fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several species of fungi can involve the adrenal glands and cause adrenal insufficiency. Histoplasmosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/63,64\">",
"     63,64",
"    </a>",
"    ] and paracoccidioidomycosis (South American blastomycosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/5,65\">",
"     5,65",
"    </a>",
"    ] are important causes of adrenal insufficiency in endemic areas. In contrast, adrenal insufficiency is rare in patients with cryptococcosis, coccidioidomycosis, and North American blastomycosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/6/43112?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\", section on 'Adrenal involvement'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adrenal glands are enlarged and may become calcified in all of these disorders.",
"     </li>",
"     <li>",
"      Recovery of adrenal function after prolonged anti-fungal treatment can occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early AIDS epidemic, the diverse endocrine manifestations of HIV infection, including adrenal insufficiency, were more often a consequence of opportunistic infections (OIs), neoplasms, or concomitant systemic illness. The widespread use of potent antiretroviral therapy (ART) has led to a decline in the incidence of endocrine complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22312?source=see_link&amp;anchor=H11#H11\">",
"     \"Pituitary and adrenal gland dysfunction in HIV-infected patients\", section on 'Alterations in adrenal function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few other infections are rare causes of primary adrenal insufficiency. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syphilis, in which gumma formation and demonstrable spirochetes may be seen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      African trypanosomiasis, unrelated to its treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"       suramin",
"      </a>",
"      , which can impair adrenal function when given in higher than the usual therapeutic doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/69\">",
"       69",
"      </a>",
"      ]. In another study of 60 patients, five had insufficient cortisol responses to ACTH stimulation on admission, and another five had an abnormal response on discharge; all improved during follow-up evaluation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HEMORRHAGIC INFARCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute adrenal insufficiency may occur as a result of bilateral adrenal infarction caused by hemorrhage or adrenal vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Adrenal hemorrhage has been associated with meningococcemia (Waterhouse-Friderichsen syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/74\">",
"     74",
"    </a>",
"    ], but Pseudomonas aeruginosa was the most common pathogen in one report of 51 children dying of sepsis and bilateral adrenal hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/75\">",
"     75",
"    </a>",
"    ]. Waterhouse-Friderichsen syndrome has also been reported with sepsis from Streptococcus pneumoniae, Neisseria gonorrhoeae, Escherichia coli, Haemophilus influenzae, and Staphylococcus aureus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26649?source=see_link\">",
"     \"Complications of Staphylococcus aureus bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bilateral adrenal hemorrhages are present in about 1 percent of routine autopsies and, before the availability of CT scanning (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63935 \" href=\"mobipreview.htm?31/35/32319\">",
"     image 1",
"    </a>",
"    ) and magnetic resonance imaging, the diagnosis was usually made at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/71,73\">",
"     71,73",
"    </a>",
"    ]. The symptoms and signs include hypotension or shock (&gt;90 percent of patients); abdominal, back, flank, or lower chest pain (86 percent); fever (66 percent); anorexia, nausea, or vomiting (47 percent); confusion or disorientation (42 percent); and abdominal rigidity or rebound (22 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major risk factors for adrenal hemorrhage include anticoagulant drug or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy (heparin-induced thrombocytopenia resulting in bilateral adrenal hemorrhage) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/76\">",
"     76",
"    </a>",
"    ], thromboembolic disease, hypercoagulable states such as antiphospholipid syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/77,78\">",
"     77,78",
"    </a>",
"    ], physical trauma, the postoperative state, sepsis, and any cause of severe stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/73,79\">",
"     73,79",
"    </a>",
"    ]. In patients treated with anticoagulants, clotting test results are usually within the therapeutic range, and spontaneous bleeding elsewhere is not evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence of occult hemorrhage, such as a sudden fall in hemoglobin and hematocrit, and progressive hyperkalemia, hyponatremia, and volume contraction should suggest the diagnosis. However, the condition is difficult to recognize clinically and, despite the often dramatic symptoms, the diagnosis is often missed. Without appropriate therapy, shock progresses to coma and death.",
"   </p>",
"   <p>",
"    The pathogenesis of adrenal hemorrhage is unclear. Increased adrenal blood flow stimulated by ACTH secreted in response to stress may play a contributory role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/73\">",
"     73",
"    </a>",
"    ]. Anticoagulation therapy is implicated in about one-third of patients, but adrenal hemorrhage occurs very rarely in patients who are anticoagulated; when it does, it is usually within the first 2 to 12 days of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/71,73,76\">",
"     71,73,76",
"    </a>",
"    ]. A case-control study (23 patients with bilateral massive adrenal hemorrhage and 92 control patients) reported that thrombocytopenia,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    use, and sepsis were the variables that were most strongly and independently associated with adrenal hemorrhage risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltration of the adrenal glands by metastatic cancer is common, probably because of their rich sinusoidal blood supply. At autopsy, adrenal metastases are found in 40 to 60 percent of patients with disseminated lung or breast cancer, 30 percent of patients with melanoma, and 14 to 20 percent of patients with stomach or colon cancer, but clinically evident adrenal insufficiency is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Similar findings occur with lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The apparent low incidence of clinical adrenal insufficiency in patients with malignant disease is due to the fact that most of the adrenal cortex must be destroyed before hypofunction becomes evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. In addition, some of the symptoms of adrenal insufficiency may mistakenly be attributed to cancer. Two small studies have suggested that 20 to 35 percent of patients with bilateral adrenal metastases have at least partial adrenal insufficiency and benefit from glucocorticoid replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several drugs may cause adrenal insufficiency by inhibiting cortisol biosynthesis. They include the anesthetic-sedative drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/87\">",
"     87",
"    </a>",
"    ], the antimycotic drugs",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/88,89\">",
"     88,89",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/90\">",
"     90",
"    </a>",
"    ], and the antiparasitic drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"     suramin",
"    </a>",
"    , which is also being tested for use in treating prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/91-93\">",
"     91-93",
"    </a>",
"    ]. These drugs usually do not cause clinically important adrenal insufficiency in patients with normal hypothalamic-pituitary-adrenal function because enzyme inhibition is incomplete and increased ACTH secretion overrides the pharmacologic blockade. However, patients with limited pituitary or adrenal reserve may develop symptomatic adrenal insufficiency.",
"   </p>",
"   <p>",
"    Other drugs accelerate the metabolism of cortisol and most synthetic glucocorticoids by inducing hepatic mixed-function oxygenase enzymes. They include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/94,95\">",
"     94,95",
"    </a>",
"    ], barbiturates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/94\">",
"     94",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/94,96,97\">",
"     94,96,97",
"    </a>",
"    ]. These drugs, therefore, can cause adrenal insufficiency in patients with limited pituitary or adrenal reserve and those with adrenal insufficiency who are receiving glucocorticoid therapy.",
"   </p>",
"   <p>",
"    The adrenocorticolytic drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    is used to treat adrenal tumors and to diminish cortisol synthesis in refractory Cushing's syndrome. It also accelerates the metabolism of halogenated synthetic steroids such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/98\">",
"     98",
"    </a>",
"    ], and can provoke adrenal insufficiency in patients with adrenal insufficiency who are receiving steroids of this type. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26295?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents\", section on 'Mitotane'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drugs that primarily suppress the CRH or ACTH production, such as glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    or opioids, or drugs that potentiate glucocorticoid effects by decreasing its metabolism (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ), are discussed under causes of secondary or tertiary adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3880?source=see_link\">",
"     \"Causes of secondary and tertiary adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia is a risk factor for acute adrenal insufficiency due to bilateral adrenal hemorrhage. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Hemorrhagic infarction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SEVERE INFLAMMATORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seriously ill patients may have lower serum cortisol concentrations during severe inflammatory disease than when there is less inflammation. In one series of six patients with critical illness, the mean basal serum cortisol was 13",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (359",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    during the inflammatory stage and 30",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (828",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    after the inflammation had subsided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/99\">",
"     99",
"    </a>",
"    ]. The mechanism by which this occurs and whether supplemental glucocorticoid therapy is of benefit are not clear. One possibility is that albumin levels reduced total cortisol levels. In one study, 21 of 36 critically ill patients with low albumin concentration (2.5 g per deciliter or less) had basal cortisol levels less than 15 mcg per deciliter (413.8 nmol per liter) but normal free levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/0/40969/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal insufficiency is a rare disorder, occurring in up to 144 people per million population. Autoimmune adrenalitis is responsible for 70 to 90 percent, with the remainder being caused by other infectious diseases, replacement by metastatic cancer or lymphoma, adrenal hemorrhage or infarction, or drugs.",
"   </p>",
"   <p>",
"    <strong>",
"     Autoimmune adrenalitis",
"    </strong>",
"    involves destruction of the cortex by both humoral and cell-mediated immune mechanisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies that react with several steroidogenic enzymes (most often 21-hydroxylase) and all three zones of the adrenal cortex are present in the serum in up to 86 percent of patients.",
"     </li>",
"     <li>",
"      Up to 50 percent of patients with autoimmune adrenalitis have additional autoimmune disorders; however, adrenal insufficiency is rarely found in patients who present with other autoimmune diseases.",
"     </li>",
"     <li>",
"      Polyglandular autoimmune syndrome type 1 (APS1) is a rare autosomal recessive disorder caused by mutations in the autoimmune regulator (AIRE) gene, which may be important in the selection and generation of regulatory T cells. Hypoparathyroidism or chronic mucocutaneous candidiasis appears by the mid-twenties, followed by adrenal insufficiency and potentially by other autoimmune diseases.",
"     </li>",
"     <li>",
"      Polyglandular autoimmune syndrome type 2 (APS2) is much more prevalent than type 1 syndrome. Primary adrenal insufficiency is its principal manifestation, but autoimmune thyroid disease and type 1 diabetes mellitus are also common. About half of the cases are familial, with polygenic modes of inheritance. It occurs later than type 1, usually presenting by age 40.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Infectious causes",
"    </strong>",
"    of adrenal insufficiency include tuberculosis, fungal infections, cytomegalovirus and Mycobacterium avium-intracellulare (usually in the context of HIV infection), syphilis, and African trypanosomiasis.",
"   </p>",
"   <p>",
"    <strong>",
"     Bilateral adrenal hemorrhage",
"    </strong>",
"    can inhibit adrenal function. This usually occurs in specific settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disseminated infection (meningococcus, Pseudomonas aeruginosa, Streptococcus, pneumoniae, Neisseria gonorrhoeae, Escherichia coli, Haemophilus influenzae, and Staphylococcus aureus).",
"     </li>",
"     <li>",
"      Clotting abnormalities (anticoagulant drug or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      therapy or coagulopathy, thromboembolic disease, hypercoagulable states such as antiphospholipid syndrome).",
"     </li>",
"     <li>",
"      Other associations include physical trauma, the postoperative state, sepsis, and severe stress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Metastatic disease with replacement of the cortex of both adrenal glands",
"    </strong>",
"    can cause adrenal insufficiency. This is most commonly associated with lung, breast, stomach, or colon cancer, melanoma, and lymphoma.",
"   </p>",
"   <p>",
"    <strong>",
"     Drugs",
"    </strong>",
"    are an important cause of primary adrenal insufficiency in patients with limited reserves who cannot overcome their effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These include drugs that inhibit cortisol biosynthesis, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"       suramin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Other drugs accelerate the metabolism of cortisol and most synthetic glucocorticoids by inducing hepatic mixed-function oxygenase enzymes (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , barbiturates,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Addison, T. On the Constitutional and Local Effects of Disease of the Supra-renal Capsules. Highley, London 1855.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/2\">",
"      Irvine, WJ, Barnes, EW. Adrenocortical insufficiency. Clin Endocrinol Metab 1972; 1:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/3\">",
"      Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison's disease. J Autoimmun 1995; 8:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/4\">",
"      Kasperlik-Zaluska AA, Migdalska B, Czarnocka B, et al. Association of Addison's disease with autoimmune disorders--a long-term observation of 180 patients. Postgrad Med J 1991; 67:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/5\">",
"      Moreira AC, Martinez R, Castro M, Elias LL. Adrenocortical dysfunction in paracoccidioidomycosis: comparison between plasma beta-lipotrophin/adrenocorticotrophin levels and adrenocortical tests. Clin Endocrinol (Oxf) 1992; 36:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/6\">",
"      Nomura K, Demura H, Saruta T. Addison's disease in Japan: characteristics and changes revealed in a nationwide survey. Intern Med 1994; 33:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/7\">",
"      Willis AC, Vince FP. The prevalence of Addison's disease in Coventry, UK. Postgrad Med J 1997; 73:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/8\">",
"      Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison's disease underestimated? J Clin Endocrinol Metab 1999; 84:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/9\">",
"      Erichsen MM, L&oslash;v&aring;s K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 2009; 94:4882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/10\">",
"      Husebye ES, L&oslash;v&aring;s K. Immunology of Addison's disease and premature ovarian failure. Endocrinol Metab Clin North Am 2009; 38:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/11\">",
"      Spinner MW, Blizzard RM, Childs B. Clinical and genetic heterogeneity in idiopathic Addison's disease and hypoparathyroidism. J Clin Endocrinol Metab 1968; 28:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/12\">",
"      Betterle C, Scalici C, Presotto F, et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol 1988; 117:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/13\">",
"      Saenger P, Levine LS, Irvine WJ, et al. Progressive adrenal failure in polyglandular autoimmune disease. J Clin Endocrinol Metab 1982; 54:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/14\">",
"      Ahonen P, Miettinen A, Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. J Clin Endocrinol Metab 1987; 64:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/15\">",
"      Baker PR, Nanduri P, Gottlieb PA, et al. Predicting the onset of Addison's disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies. Clin Endocrinol (Oxf) 2012; 76:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/16\">",
"      Blizzard RM, Chee D, Davis W. The incidence of adrenal and other antibodies in the sera of patients with idiopathic adrenal insufficiency (Addison's disease). Clin Exp Immunol 1967; 2:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/17\">",
"      McHardy-Young S, Lessof MH, Maisey MN. Serum TSH and thyroid antibody studies in Addison's disease. Clin Endocrinol (Oxf) 1972; 1:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/18\">",
"      Nerup J. Addison's disease--clinical studies. A report fo 108 cases. Acta Endocrinol (Copenh) 1974; 76:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/19\">",
"      Myhre AG, Undlien DE, L&oslash;v&aring;s K, et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab 2002; 87:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/20\">",
"      Brewer KW, Parziale VS, Eisenbarth GS. Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency. N Engl J Med 1997; 337:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/21\">",
"      Marks SD, Girgis R, Couch RM. Screening for adrenal antibodies in children with type 1 diabetes and autoimmune thyroid disease. Diabetes Care 2003; 26:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/22\">",
"      Yu L, Brewer KW, Gates S, et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab 1999; 84:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/23\">",
"      Triolo TM, Baschal EE, Armstrong TK, et al. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. J Clin Endocrinol Metab 2009; 94:4517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/24\">",
"      Barker JM, Ide A, Hostetler C, et al. Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison's disease in a high-risk population. J Clin Endocrinol Metab 2005; 90:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/25\">",
"      Elfstr&ouml;m P, Montgomery SM, K&auml;mpe O, et al. Risk of primary adrenal insufficiency in patients with celiac disease. J Clin Endocrinol Metab 2007; 92:3595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/26\">",
"      Myhre AG, Aarset&oslash;y H, Undlien DE, et al. High frequency of coeliac disease among patients with autoimmune adrenocortical failure. Scand J Gastroenterol 2003; 38:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/27\">",
"      Ahonen P, Myll&auml;rniemi S, Sipil&auml; I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/28\">",
"      Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981; 60:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/29\">",
"      Trence DL, Morley JE, Handwerger BS. Polyglandular autoimmune syndromes. Am J Med 1984; 77:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/30\">",
"      Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004; 350:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/31\">",
"      Scott HS, Heino M, Peterson P, et al. Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol 1998; 12:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/32\">",
"      Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet 1997; 17:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/33\">",
"      Heino M, Scott HS, Chen Q, et al. Mutation analyses of North American APS-1 patients. Hum Mutat 1999; 13:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/34\">",
"      Meloni A, Perniola R, Fa&agrave; V, et al. Delineation of the molecular defects in the AIRE gene in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients from Southern Italy. J Clin Endocrinol Metab 2002; 87:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/35\">",
"      Bj&ouml;rses P, Aaltonen J, Horelli-Kuitunen N, et al. Gene defect behind APECED: a new clue to autoimmunity. Hum Mol Genet 1998; 7:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/36\">",
"      Gylling M, Tuomi T, Bj&ouml;rses P, et al. ss-cell autoantibodies, human leukocyte antigen II alleles, and type 1 diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2000; 85:4434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/37\">",
"      DeVoss JJ, Anderson MS. Lessons on immune tolerance from the monogenic disease APS1. Curr Opin Genet Dev 2007; 17:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/38\">",
"      Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997; 17:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/39\">",
"      Rosatelli MC, Meloni A, Meloni A, et al. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Hum Genet 1998; 103:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/40\">",
"      Li Y, Song YH, Rais N, et al. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest 1996; 97:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/41\">",
"      Kifor O, McElduff A, LeBoff MS, et al. Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab 2004; 89:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/42\">",
"      S&ouml;derbergh A, Myhre AG, Ekwall O, et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2004; 89:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/43\">",
"      B&ouml;ckle BC, Wilhelm M, M&uuml;ller H, et al. Oral mucous squamous cell carcinoma-an anticipated consequence of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J Am Acad Dermatol 2010; 62:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/44\">",
"      Chen S, Sawicka J, Betterle C, et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. J Clin Endocrinol Metab 1996; 81:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/45\">",
"      Betterle C, Greggio NA, Volpato M. Clinical review 93: Autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1998; 83:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/46\">",
"      Ekwall O, Hedstrand H, Grimelius L, et al. Identification of tryptophan hydroxylase as an intestinal autoantigen. Lancet 1998; 352:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/47\">",
"      H&ouml;genauer C, Meyer RL, Netto GJ, et al. Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I. N Engl J Med 2001; 344:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/48\">",
"      Husebye ES, Gebre-Medhin G, Tuomi T, et al. Autoantibodies against aromatic L-amino acid decarboxylase in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 1997; 82:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/49\">",
"      Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003; 88:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/50\">",
"      Ward L, Paquette J, Seidman E, et al. Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. J Clin Endocrinol Metab 1999; 84:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/51\">",
"      Asherson RA, Hughes GR. Recurrent deep vein thrombosis and Addison's disease in \"primary\" antiphospholipid syndrome. J Rheumatol 1989; 16:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/52\">",
"      Tucker WS Jr, Niblack GD, McLean RH, et al. Serositis with autoimmune endocrinopathy: clinical and immunogenetic features. Medicine (Baltimore) 1987; 66:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/53\">",
"      Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 1998; 114:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/54\">",
"      Guttman, PH. Addison's disease. A statistical analysis of five hundred and sixty-six cases and a study of the pathology. Arch Pathol 1930; 10:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/55\">",
"      Vita JA, Silverberg SJ, Goland RS, et al. Clinical clues to the cause of Addison's disease. Am J Med 1985; 78:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/56\">",
"      Laureti S, Aubourg P, Calcinaro F, et al. Etiological diagnosis of primary adrenal insufficiency using an original flowchart of immune and biochemical markers. J Clin Endocrinol Metab 1998; 83:3163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/57\">",
"      Sun ZH, Nomura K, Toraya S, et al. Clinical significance of adrenal computed tomography in Addison's disease. Endocrinol Jpn 1992; 39:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/58\">",
"      Villabona CM, Sahun M, Ricart W, et al. Tuberculous Addison's disease. Utility of CT in diagnosis and follow-up. Eur J Radiol 1993; 17:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/59\">",
"      Guo YK, Yang ZG, Li Y, et al. Addison's disease due to adrenal tuberculosis: contrast-enhanced CT features and clinical duration correlation. Eur J Radiol 2007; 62:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/60\">",
"      Penrice J, Nussey SS. Recovery of adrenocortical function following treatment of tuberculous Addison's disease. Postgrad Med J 1992; 68:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/61\">",
"      Bhatia E, Jain SK, Gupta RK, Pandey R. Tuberculous Addison's disease: lack of normalization of adrenocortical function after anti-tuberculous chemotherapy. Clin Endocrinol (Oxf) 1998; 48:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/62\">",
"      G&uuml;lmez I, Kele��timur F, Durak AC, Ozesmi M. Changes in the size of adrenal glands in acute pulmonary tuberculosis with therapy. Endocr J 1996; 43:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/63\">",
"      Sarosi GA, Voth DW, Dahl BA, et al. Disseminated histoplasmosis: results of long-term follow-up. A center for disease control cooperative mycoses study. Ann Intern Med 1971; 75:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/64\">",
"      Washburn RG, Bennett JE. Reversal of adrenal glucocorticoid dysfunction in a patient with disseminated histoplasmosis. Ann Intern Med 1989; 110:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/65\">",
"      Abad A, Gomez I, Velez P, Restrepo A. Adrenal function in paracoccidioidomycosis: a prospective study in patients before and after ketoconazole therapy. Infection 1986; 14:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/66\">",
"      Walker BF, Gunthel CJ, Bryan JA, et al. Disseminated cryptococcosis in an apparently normal host presenting as primary adrenal insufficiency: diagnosis by fine needle aspiration. Am J Med 1989; 86:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/67\">",
"      MALONEY PJ. Addison's disease due to chronic disseminated coccidioidomycosis. AMA Arch Intern Med 1952; 90:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/68\">",
"      ABERNATHY RS, MELBY JC. Addison's disease in North American blastomycosis. N Engl J Med 1962; 266:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/69\">",
"      Heppner C, Petzke F, Arlt W, et al. Adrenocortical insufficiency in Rhodesian sleeping sickness is not attributable to suramin. Trans R Soc Trop Med Hyg 1995; 89:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/70\">",
"      Blum JA, Schmid C, Hatz C, et al. Sleeping glands? - The role of endocrine disorders in sleeping sickness (T.b. gambiense Human African Trypanosomiasis). Acta Trop 2007; 104:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/71\">",
"      Xarli VP, Steele AA, Davis PJ, et al. Adrenal hemorrhage in the adult. Medicine (Baltimore) 1978; 57:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/72\">",
"      Rao RH, Vagnucci AH, Amico JA. Bilateral massive adrenal hemorrhage: early recognition and treatment. Ann Intern Med 1989; 110:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/73\">",
"      Streeten, DHP. Adrenal hemorrhage. Endocrinologist 1996; 6:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/74\">",
"      Migeon CJ, Kenny FM, Hung W, Voorhess ML. Study of adrenal function in children with meningitis. Pediatrics 1967; 40:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/75\">",
"      MARGARETTEN W, NAKAI H, LANDING BH. Septicemic adrenal hemorrhage. Am J Dis Child 1963; 105:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/76\">",
"      Rosenberger LH, Smith PW, Sawyer RG, et al. Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. Crit Care Med 2011; 39:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/77\">",
"      Caron P, Chabannier MH, Cambus JP, et al. Definitive adrenal insufficiency due to bilateral adrenal hemorrhage and primary antiphospholipid syndrome. J Clin Endocrinol Metab 1998; 83:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/78\">",
"      Espinosa G, Santos E, Cervera R, et al. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore) 2003; 82:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/79\">",
"      Kovacs KA, Lam YM, Pater JL. Bilateral massive adrenal hemorrhage. Assessment of putative risk factors by the case-control method. Medicine (Baltimore) 2001; 80:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/80\">",
"      Cedermark BJ, Blumenson LE, Pickren JW, et al. Ths significance of metastases to the adrenal glands in adenocarcinoma of the colon and rectum. Surg Gynecol Obstet 1977; 144:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/81\">",
"      Redman BG, Pazdur R, Zingas AP, Loredo R. Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis. Cancer 1987; 60:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/82\">",
"      Seidenwurm DJ, Elmer EB, Kaplan LM, et al. Metastases to the adrenal glands and the development of Addison's disease. Cancer 1984; 54:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/83\">",
"      Serrano S, Tejedor L, Garcia B, et al. Addisonian crisis as the presenting feature of bilateral primary adrenal lymphoma. Cancer 1993; 71:4030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/84\">",
"      Huminer D, Garty M, Lapidot M, et al. Lymphoma presenting with adrenal insufficiency. Adrenal enlargement on computed tomographic scanning as a clue to diagnosis. Am J Med 1988; 84:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/85\">",
"      Barker, NW. The pathologic anatomy in twenty-eight cases of Addison's disease. Arch Pathol 1929; 8:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/86\">",
"      Cedermark BJ, Sj&ouml;berg HE. The clinical significance of metastases to the adrenal glands. Surg Gynecol Obstet 1981; 152:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/87\">",
"      Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/88\">",
"      Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/89\">",
"      Riedl M, Maier C, Zettinig G, et al. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 2006; 154:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/90\">",
"      LIDDLE GW, ISLAND D, LANCE EM, HARRIS AP. Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation. J Clin Endocrinol Metab 1958; 18:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/91\">",
"      Ashby H, DiMattina M, Linehan WM, et al. The inhibition of human adrenal steroidogenic enzyme activities by suramin. J Clin Endocrinol Metab 1989; 68:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/92\">",
"      Stein CA, Saville W, Yarchoan R, et al. Suramin and function of the adrenal cortex. Ann Intern Med 1986; 104:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/93\">",
"      Kobayashi K, Weiss RE, Vogelzang NJ, et al. Mineralocorticoid insufficiency due to suramin therapy. Cancer 1996; 78:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/94\">",
"      Elias AN, Gwinup G. Effects of some clinically encountered drugs on steroid synthesis and degradation. Metabolism 1980; 29:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/95\">",
"      Keilholz U, Guthrie GP Jr. Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. Am J Med Sci 1986; 291:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/96\">",
"      Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 1984; 59:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/97\">",
"      Ediger SK, Isley WL. Rifampicin-induced adrenal insufficiency in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment. Postgrad Med J 1988; 64:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/98\">",
"      Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 1987; 27:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/99\">",
"      Mackenzie JS, Burrows L, Burchard KW. Transient hypoadrenalism during surgical critical illness. Arch Surg 1998; 133:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/0/40969/abstract/100\">",
"      Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 166 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40969=[""].join("\n");
var outline_f40_0_40969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AUTOIMMUNE ADRENALITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1925578\">",
"      Destruction of adrenal cortex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1925571\">",
"      Sex differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1925564\">",
"      Early findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1925585\">",
"      Other endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Polyglandular autoimmune syndrome type I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1925657\">",
"      - Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1925664\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Polyglandular autoimmune syndrome type II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1925680\">",
"      - Affected endocrine organs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INFECTIOUS ADRENALITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disseminated fungal infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HEMORRHAGIC INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SEVERE INFLAMMATORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/166\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/166|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/35/32319\" title=\"diagnostic image 1\">",
"      Adrenal hemorrhage CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/166|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/1/10258\" title=\"picture 1\">",
"      Chronic mucocutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/166|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/57/17308\" title=\"table 1\">",
"      Causes of primary adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/13/35035\" title=\"table 2\">",
"      Autoimmune disorders with adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/25/9629\" title=\"table 3\">",
"      Polyglandular autoimmune syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3880?source=related_link\">",
"      Causes of secondary and tertiary adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26649?source=related_link\">",
"      Complications of Staphylococcus aureus bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=related_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/6/43112?source=related_link\">",
"      Pathogenesis and clinical manifestations of disseminated histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9896?source=related_link\">",
"      Pathogenesis of autoimmune adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23976?source=related_link\">",
"      Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26295?source=related_link\">",
"      Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22312?source=related_link\">",
"      Pituitary and adrenal gland dysfunction in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12408?source=related_link\">",
"      Unusual causes of adrenal insufficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_0_40970="Pemphigus vulgaris erosions";
var content_f40_0_40970=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51868%7EDERM%2F63170%7EDERM%2F74842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51868%7EDERM%2F63170%7EDERM%2F74842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erosions and small blisters are present in this image taken from a patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions on the trunk skin of this patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Widespread erosions are present on the skin in this patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40970=[""].join("\n");
var outline_f40_0_40970=null;
var title_f40_0_40971="Risk GI procedure conditions";
var content_f40_0_40971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Condition-related risk of thromboembolic complications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High-risk conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial fibrillation associated with valvular heart disease (including the presence of a mechanical valve)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial fibrillation associated with congestive heart failure or a left ventricular ejection fraction of &lt;35 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial fibrillation associated with a history of a thromboembolic event",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial fibrillation associated with hypertension, diabetes, or age &gt;75 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechanical valves in the mitral position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechanical valves in patients who have had a prior thromboembolic event",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary stents placed within one year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute coronary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonstented percutaneous coronary intervention after myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low-risk conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep vein thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic or paroxysmal atrial fibrillation that is not associated with valvular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bioprosthetic valves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechanical valves in the aortic position",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Anderson MA, Ben-Menachem T, Gan SI, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70:1060. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40971=[""].join("\n");
var outline_f40_0_40971=null;
var title_f40_0_40972="Lung allocation score";
var content_f40_0_40972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lung allocation score for candidates age 12 and older",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Step 1: The transplant center enters the factors in part 1 below on the UNet web site. A Cox proportional hazards model is used to derive an estimate of the number of days a recipient would be expected to live during the first year post transplant. This is the",
"       <strong>",
"        post transplant survival measure",
"       </strong>",
"       .",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Step 2: The transplant center enters the factors in part 2 below on the UNet web site.  A Cox proportional hazards model is used to derive an estimate of the expected number of days a candidate would live without a transplant during an additional year on the waitlist. This is the",
"       <strong>",
"        waitlist survival measure",
"       </strong>",
"       .",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Step 3: Using the values derived in steps 1 and 2, the transplant benefit measure is calculated:",
"       </p>",
"       <p>",
"        Transplant benefit = post transplant survival (days) - waitlist survival (days).",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Step 4: The",
"       <strong>",
"        raw allocation score",
"       </strong>",
"       = transplant benefit (days) - waitlist survival (days).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Step 5: The",
"       <strong>",
"        lung allocation score",
"       </strong>",
"       is derived by normalizing the raw allocation score to a range of 0 to 100.  The higher the score the higher the priority.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Part 1 Post transplant survival measure:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. FVC (Group B, D)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2.  PCW pressure &ge;20 (Group D)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3.  Continuous mechanical ventilation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4.  Age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5.  Serum creatinine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6.  Functional Status (NYHA class)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7.  Diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Part 2 Waiting list urgency measure:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1.  Forced vital capacity (FVC)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2.  Pulmonary artery systolic pressure (Group A, C, D)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3.  Supplemental O2 required at rest (Group A, C, D) *",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4.  Age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5.  Body mass index (BMI)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6.  Diabetes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7.  Functional status",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8.  Six-minute walk distance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9.  Continuous mechanical ventilation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10.  Diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11.  pCO2&bull;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *Group A: COPD, alpha-1-antitrypsin, emphysema, lymphangioleiomyomatosis, bronchiectasis, sarcoidosis with a mean PA pressure &le;30 mmHg.",
"     <br>",
"      Group B: Pulmonary hypertension (IPAH, Eisenmenger's syndrome, etc).",
"      <br>",
"       Group C: Cystic fibrosis, immunodeficiency disorders (eg, Hypogammaglobulinemia).",
"       <br>",
"        Group D: IPF, other causes of pulmonary fibrosis, sarcoidosis with PA &gt;30 mmHg, obliterative bronchiolitis (non-retransplant).",
"        <br>",
"         &bull; pCO2 may be taken from arterial, capillary or venous measurement. If venous, 6 mmHg will be subtracted to produce an equivalent arterial value. This a adjusted for any change in value over time that is greater than 15 percent.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: file://www.unos.org/resources/frm_LAS_Calculator.asp.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40972=[""].join("\n");
var outline_f40_0_40972=null;
var title_f40_0_40973="Dx accuracy UTI sx children";
var content_f40_0_40973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Likelihood ratios for selected symptoms and signs of urinary tract infection in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptoms and signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive likelihood ratio*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Negative likelihood ratio",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Symptoms and signs in children aged 0 to 24 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonblack race",
"       </td>",
"       <td>",
"        1.4 (95% CI 1.1-1.8)",
"       </td>",
"       <td>",
"        0.52 (95% CI 0.29-0.73)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        History of prior UTI",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         2.3 (95% CI 0.3-17.4)",
"        </p>",
"        <p>",
"         2.9 (95% CI 1.2-7.1)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0.97 (95% CI 0.89-1.07)",
"        </p>",
"        <p>",
"         0.95 (95% CI 0.89-1.02)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temperature (T) &gt;39&deg;C",
"       </td>",
"       <td>",
"        1.4 (95% CI 1.2-1.7)",
"       </td>",
"       <td>",
"        0.78 (95% CI 0.65-0.81)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T &gt;40&deg;C",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         3.2 (95% CI 0.7-15.6)",
"        </p>",
"        <p>",
"         3.3 (95% CI 1.3-8.3)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0.93 (95% CI 0.8-1.08)",
"        </p>",
"        <p>",
"         0.66 (95% CI 0.35-1.25)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fever &gt;24 hours",
"       </td>",
"       <td>",
"        2.0 (95% CI 1.4-2.9)",
"       </td>",
"       <td>",
"        0.90 (95% CI 0.83-0.97)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fever &gt;48 hours",
"       </td>",
"       <td>",
"        1.3 (95% CI 0.8-1.9)",
"       </td>",
"       <td>",
"        0.95 (95% CI 0.85-1.06)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ill appearance (infants &lt;3 months)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         0.59 (95% CI 0.22-1.59)",
"        </p>",
"        <p>",
"         1.1 (95% CI 0.9-1.3)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         1.03 (95% CI 0.99-1.08)",
"        </p>",
"        <p>",
"         0.95 (95% CI 0.84-1.08)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ill appearance (children 3-24 months)",
"       </td>",
"       <td>",
"        1.9 (95% CI 1.5-2.4)",
"       </td>",
"       <td>",
"        0.68 (95% CI 0.53-0.88)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suprapubic tenderness",
"       </td>",
"       <td>",
"        4.4 (95% CI 1.6-12.4)",
"       </td>",
"       <td>",
"        0.96 (95% CI 0.9-1.01)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No other source for fever on examination",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1.4 (95% CI 1.1-1.8)",
"       </td>",
"       <td>",
"        0.69 (95% CI 0.55-0.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uncircumcised male infants",
"       </td>",
"       <td>",
"        2.8 (95% CI 1.9-4.3)",
"       </td>",
"       <td>",
"        0.33 (95% CI 0.18-0.63)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Combination of symptoms and signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        T &gt;39&deg;C for &gt;48 hours and no potential source for fever",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        4 (95% CI 1.2-13)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        T &gt;38&deg;C for &gt;48 hours and no potential source for fever",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        3.6 (95% CI 1.4-8.8)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        T &gt;39&deg;C and no potential source for fever",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        2 (95% CI 1.8-2.4)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        T &gt;39&deg;C for &gt;48 hours",
"       </td>",
"       <td>",
"        1.7 (95% CI 0.9-2.9)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        T &gt;39&deg;C with a potential source for fever",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        0.86 (95% CI 0.5-1.47)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent2\">",
"        T &lt;39&deg;C and potential source for fever",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        0.37 (95% CI 0.16-0.85)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Symptoms and signs in verbal children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abdominal pain",
"       </td>",
"       <td>",
"        6.3 (95% CI 2.5-16)",
"       </td>",
"       <td>",
"        0.8 (95% CI 0.65-0.99)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Back pain",
"       </td>",
"       <td>",
"        3.6 (95% CI 2.1-6.1)",
"       </td>",
"       <td>",
"        0.84 (95% CI 0.75-0.95)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dysuria/frequency",
"       </td>",
"       <td>",
"        2.2 (95% CI 1.1-4.3)",
"       </td>",
"       <td>",
"        0.71 (95% CI 0.45-1.13)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        New-onset urinary incontinence",
"       </td>",
"       <td>",
"        4.6 (95% CI 2.8-7.6)",
"       </td>",
"       <td>",
"        0.79 (95% CI 0.69-0.90)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The positive likelihood ratio is the probability that a child with UTI will have the symptom or sign divided by the probability that a child without a UTI will have the symptom or sign (eg, true positive rate/false positive rate).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The negative likelihood ratio is the probability that a child with a UTI will not have the symptom or sign divided by the probability that a child without UTI will not have the symptom or sign (eg, the false negative rate/true negative rate).",
"     <br/>",
"     &Delta; The likelihood ratios from individual studies are presented separately.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Other potential sources of fever included illnesses such as upper respiratory infection, acute otitis media, and acute gastroenteritis.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Shaikh N, Morone NE, Lopez J, et al. Does this child have a urinary tract infection? JAMA 2007; 298:2895.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40973=[""].join("\n");
var outline_f40_0_40973=null;
var title_f40_0_40974="Nail bed repair";
var content_f40_0_40974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nail bed repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 207px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The nail bed is easily torn with the suture needle. Optimal results are typically achieved if the needle is passed from the distal to the proximal aspect of the nail bed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter M. Antevy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40974=[""].join("\n");
var outline_f40_0_40974=null;
var title_f40_0_40975="Hot liquid balloon ablation";
var content_f40_0_40975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hot liquid balloon endometrial ablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thermachoice system",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_0_40975=[""].join("\n");
var outline_f40_0_40975=null;
